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ABSTRACT
Die vorliegende Arbeit gewährt Einblick in biochemische Signalwege, die in verschie-
denen Zellsystemen zu apoptotischem Zelltod nach Behandlung mit Zytostatika füh-
ren. Die Arbeit überspannt zwei Bereiche: die Identifizierung des initiierenden
Signalweges bei Zytostatika-induzierter Apoptose in der humanen B-Zell Lymphom
Zellinie BJAB und Einblick in Apoptose-bezogene Ereignisse, die durch Zytostatikabe-
handlung induziert werden. Die Verifizierung, daß Zytostatikabehandlung nicht nur das
Zellwachstum hemmt sondern auch Apoptose induziert, ist der erste Schritt.
Der erste Bereich behandelt spezifische Ereignisse/Proteine die mit der Apoptose as-
soziiert sind: Um den initiierenden Signalweg bei Zytostatika-induzierter Apoptose zu
bestimmen, wird die Kaskade der apoptotischen Ereignisse am Endpunkt der Apopto-
se beginnend aufgedeckt: Zytostatika-induzierter Zelltod wurde mittels Trypan-Blau
Färbung untersucht und die Quantifizierung ergab, daß etwa 60% der behandelten
BJAB-Zellen nach 72 Std. sterben. Weitere Charakteristika der Apoptose wurden, dem
Signalweg aufwärts folgend, mittels immunchemischer, biochemischer und zellbiologi-
scher Methoden untersucht. Die Fragmentierung der DNA wurde durch durchflußzyto-
metrische Analyse bestimmt; Aktivierung der Caspasen wurde sowohl durch Western-
Blot Analyse als auch in Caspase-spezifischen Aktivitäts-Assays detektiert. Hierdurch
wird gezeigt, daß während der Apoptose die DNA degradiert wird, was in einer gestei-
gerten Zahl hypodiploider Zellen resultiert, die bis zu 60% nach 72 Std. erreichen. Ei-
nes der Caspase-Substrate, Poly-(ADP-Ribose)-Polymerase (PARP), wird spezifisch
während der Zytostatika-induzierten Apoptose in BJAB-Zellen gespalten, was durch
Western-Blot Analyse gezeigt wird. Desweiteren werden Caspase-3-, Caspase-9- und
Caspase-8-Aktivierung mittels Western-Blot Analyse detektiert. Die Prozessierung der
Caspase-8 warf die Frage auf, welches der Startpunkt der Caspase-Kaskade bei Zy-
tostatika-induzierter Apoptose ist, da Caspase-8 im allgemeinen als die am Anfang der
Protease-Kaskade stehende Initiator-Caspase bei der CD95/Fas induzierten Apoptose
betrachtet wird. Der Zusammenbruch des mitochondrialen Membranpotentials, ein Er-
eignis, das oberhalb der Aktivierung von Caspase-9 gelegen ist, wurde mittels durch-
flußzytometrischer Analyse untersucht unter Gebrauch des Farbstoffes JC-1
(5,5´,6,6´-tetrachloro-1,1´,3,3´-tetraethyl-benzimidazolylcarbocyanin iodide), der sen-
sitiv auf Veränderungen im mitochondrialen Membranpotential reagiert. Für BJAB-Zel-
len konnte ein signifikanter Verlust des mitochondrialen Membranpotentials gezeigt
werden, der in 80% der mit Taxol-behandelten und 60% der Epirubizin-behandelten
Zellen nach 72 Std. nachgewiesen wurde. Um im weiteren die Rolle der Caspase-8
Prozessierung zu untersuchen, wurden stabil transfizierte Zellen, die eine dominant-
negative Mutante des Adaptermoleküls FADD (Fas assoziiertes Protein mit Todesdo-
mäne) exprimieren, eingesetzt. FADD ist notwendig zur Formierung des Todes-indu-4
zierenden Signalkomplexes (DISC) im CD95/Fas Signalweg; Überexpression der
dominant-negativen Mutante des Moleküls FADD (FADDdn) unterbricht die Weiterlei-
tung des CD95/Fas-Todessignals ins Zytoplasma und blockiert somit die Apoptose.
Mittels Western-Blot erzielte Ergebnisse zeigen, daß die Transfektion mit FADDdn kei-
nen signifikanten Einfluß auf die Caspase-8 Prozessierung hat. Die CD95/Fas unab-
hängige Prozessierung der Caspase-8 wurde in einem zellfreien Extrakt bestätigt, in
dem die mitochondriale Induktion der Caspasen-Kaskade in vitro nachgestellt werden
kann. Western-Blot Analyse und Substratassays mit Caspase-spezifischen Peptidsub-
straten der in vivo und in vitro Experimente lokalisieren die Caspase-8-Prozessierung
unterhalb der Procaspase-3 in den verschiedenen humanen B-Zell Lymphom Zellinien,
die zum Einsatz kamen: BJAB/mock, BJAB/FADDdn, NALM6 und REH. Diese Tatsa-
che wurde zudem durch den Einsatz spezifischer Caspase-Inhibitoren unterstrichen
und durch die immunchemische Ausfällung der Procaspase-3 aus zellfreien Extrakten
vor der Induktion der mitochondrialen Caspase-Kaskade. Die Prozessierung der Cas-
pase-8 ist stark vermindert in Zytostatika-behandelten Zellen, die in Gegenwart von Z-
DEVD-fmk, einem Caspase-3 spezifischen irreversiblen Inhibitor, inkubiert wurden. Im-
munchemische Depletion der Caspase-3 von zellfreien Extrakten blockiert die Prozes-
sierung der Caspase-8 nach Initiierung der mitochondrialen Caspase-Kaskade.
Der zweite Bereich befaßt sich mit einem generelleren Ansatz: Ein hochauflösender
Zugang zur Proteinanalyse wurde eingesetzt um einen Einblick in den Zytostatika-in-
duzierten Zelltod in BJAB/mock Zellen zu erhalten. Die zweidimensionale Polyacryl-
amid-Gelelektrophorese (2DE PAGE) von Proben Zytostatika-behandelter Zellen und
von Kontrollproben wurde durchgeführt und die Ergebnisse mittels subtraktiver Analy-
se ausgewertet. Diese Experimente führten zur Identifikation einiger Caspase-Substra-
te wie β-Aktin und Nucleolin. D4-GDI (rho GDP Dissoziationsinhibitor 2) wird ebenfalls
als eines dieser Substrate gezeigt und extensiver experimenteller Aufwand wurde be-
trieben, um die in vivo verantwortliche Caspase festzumachen. Durch den Einsatz des
Caspase-3 spezifischen Inhibitors Z-DEVD-fmk konnte gezeigt werden, daß D4-GDI in
kultivierten, apoptotischen BJAB-Zellen von aktiver Caspase-3 gespalten wird. Dieses
Ergebnis wurde in zellfreien Extrakten durch den Einsatz des Caspase-3 spezifischen
Substrates Ac-DEVD-pNA als kompetitiver Inhibitor und immunchemischer Depletion
von Procaspase-3 bestätigt. Beides führt zu einer verminderten Spaltung von D4-GDI.
Da über D4-GDI bekannt ist, daß es ebenfalls als Substrat für Caspase-1 fungiert, wur-
de die Aktivierung von Procaspase-1 nach Zytostatikabehandlung in BJAB-Zellen un-
tersucht. Die Western-Blot Analyse zeigte keinen Konzentrationsanstieg für die aktive
Untereinheit p20 der Caspase-1. Im Aktivitätsassay, in dem das Caspase-1 spezifi-
sche Substrat Ac-WEHD-pNA eingesetzt wurde, konnte keine signifikante Spaltungs-
aktivität detektiert werden. Schließlich zeigte die massenspektrometrische Analyse
des resultierenden D4-GDI Fragmentes, daß Caspase-3 und nicht Caspase-1 verant-5
wortlich für die Spaltung von D4-GDI nach Zytostatikabehandlung von BJAB-Zellen ist.
Das Peptid, welches die Caspase-1 Erkennungssequenz enthält, wurde in dem Apo-
ptose-assoziierten D4-GDI Fragment detektiert. Darüberhinaus wurde demonstriert,
daß der apoptotische Zelltod keinerlei Konsequenzen für Rho-GDI 1, ein Protein, das
hohe Homologie zu D4-GDI aufweist, birgt. Hierdurch wird bekräftigt, daß die Spaltung
zellulärer Proteine während der Apoptose hochspezifisch ist.
Die Ergebnisse der 2DE PAGE weisen darauf hin, daß die angewandte Methodologie
nicht ausreicht, um Veränderungen regulatorischer Faktoren auf Proteinebene nach
Zytostatikabehandlung von BJAB-Zellen zu detektieren. Signifikante Veränderungen
der Proteinkonzentration konnten ausschließlich für Caspase-Substrate detektiert wer-
den. Daher wurde versucht, dieses Problem zu lösen, indem die Probenpräparation
spezifischer gestaltet wurde. Annexin-V gekoppelte magnetische Mikrokügelchen wur-
den eingesetzt, um apoptotische von nicht-apoptotischen Zellen zu trennen. Diese Me-
thode reichert apoptotische Zellen durch Bindung an Phosphatidylserin (PS) an,
welches aufgrund der Apoptose-Induktion auf der Außenmembran exponiert wird. Al-
lerdings scheint die Exposition von PS ein spätes Ereignis bei Zytostatika-induzierter
Apoptose in BJAB/mock-Zellen zu sein, da diese Methode nicht zur Identifikation regu-
latorischer Proteine während des apoptotischen Zelltodes führte. Dies wird aus der
Tatsache geschlossen, daß die Spaltung von Caspase-Substraten in PS-negativen
Zellen eindeutig detektiert werden konnte.
In einem weiteren Versuch wurde die Visualisierungstechnik durch metabolische Mar-
kierung der Proteine mit 35S-Methionin und 35S-Cystein sensitiviert. Durch diese Me-
thode wird die Detektionsgrenze herabgesetzt und Veränderungen innerhalb eines
spezifischen Zeitfensters können beobachtet werden. Die erhaltenen Ergebnisse zei-
gen deutlich, daß das metabolische Markieren nützlich für die Detektion regulatori-
scher Proteine ist, dafür jedoch andere Probleme mit sich bringt: In den meisten Fällen
ist die Menge an regulatorischem Protein weit geringer als diejenige, welche für eine
massenspektrometrische Analyse und Identifikation notwendig ist. In den bisherigen
Experimenten konnte ein Spot detektiert werden, der signifikante Intensitätsunter-
schiede in Autoradiographien von 2DE PAGE Gelen aufweist. Die Identifizierung war
bis jetzt allerdings nicht möglich. 6
ABSTRACT
This thesis will elucidate the biochemical pathways leading to apoptotic cell death after
cytostatic drug-treatment of different cellular systems. The thesis will cover two areas:
the identification of the initiating signalling pathway of drug-induced apoptosis in the hu-
man B-cell lymphoma cell line BJAB, and insights into apoptosis related events in-
duced by cytostatic drug-treatment. Verification that cytostatic drug treatment not only
inhibits cell growth but induces apoptosis is the first step.
The one area governs questions regarding specific events and/or proteins associated
with apoptosis:
To elucidate the initiating pathway of drug-induced apoptosis the cascade of apoptotic
events is unravelled starting at the most downstream event of apoptosis: drug-induced
cell death was examined using the trypan blue exclusion assay and quantification re-
vealed that about 60 % of treated BJAB cells died after 72 hs. Further hallmarks of ap-
optosis following the signalling pathways to far more upstream-located events were
investigated using immunochemical, biochemical and cell biological methods. DNA
fragmentation was determined using flow cytometric analysis; activation of caspases
was detected by western blot analysis and specific caspase activity assays. Thereby it
was shown that during apoptosis DNA is degraded resulting in an increased number of
hypodiploid cells reaching up to 60 % after 72 hs. One of the most downstream sub-
strates of caspases, PARP (poly-ADP ribose polymerase), was specifically cleaved
during drug induced apoptosis in BJAB cells as shown by Western blot analysis. More-
over, caspase-3, caspase-9 and caspase-8 activation was detected by western blot
analysis. Processing of caspase-8  rose the question for the initiating point of the
caspase cascade during drug-induced apoptosis because caspase-8 is reported to be
the most upstream-located initiator caspase in CD95/Fas-induced apoptosis. Disrup-
tion of mitochondrial membrane potential, an event that is located upstream of
caspase-9 activation, was examined by flow cytometric analysis using the mitochondri-
al membrane potential sensitive dye JC-1 (5,5´,6,6´-tetrachloro-1,1´,3,3´-tetraethyl-
benzimidazolylcarbocyanin iodide) and BJAB/mock cells were shown to undergo sig-
nificant loss of mitochondrial membrane potential reaching up to 80 % in taxol- and 60
% in epirubicin treated cells after 72 hs. To further investigate the role of caspase-8 pro-
cessing stably transfected cells, harbouring a dominant-negative mutant of the adaptor
molecule FADD (Fas associated protein with death domain), were used. FADD is nec-
essary for formation of the death inducing signalling complex (DISC) in the CD95/Fas
signalling pathway; overexpression of the dominant negative mutant of FADD (FAD-
Ddn) abrogates transmission of  the CD95/Fas death signal into the cytoplasm and
blocks apoptosis. Results derived from western blot analysis show that transfection
with FADDdn had no significant influence on caspase-8 processing. CD95/Fas inde-7
pendent processing of caspase-8 was confirmed using a cell free extract system which
mimics the mitochondrial initiated caspase cascade. Western blot analysis and
caspase substrate assays from the in vivo and in vitro experiments locate caspase-8
processing downstream of caspase-3 in different human B cell lymphoma cell lines
used: BJAB/mock, BJAB/FADDdn, NALM6 and REH. This fact is strengthened by the
usage of specific caspase inhibitors and by depleting caspase-3 from cell free extracts
prior to induction of the mitochondrial caspase cascade. Caspase-8 processing was di-
minished in drug-treated cells incubated in the presence of Z-DEVD-fmk, a caspase-3
specific irreversible inhibitor. Immunochemical depletion of caspase-3 from cell free ex-
tracts blocked caspase-8 processing after initiation of the mitochondrial apoptotic cas-
cade. 
The second area governs a more general setup: A high resolution approach to protein
analysis was used to gain insight into cytostatic drug-induced cell death of BJAB/mock
cells. 2DE-PAGE analysis of samples derived from drug-treated cells and control sam-
ples was performed and evaluated by subtractive analysis. These experiments lead to
the identification of some caspase substrates, such as β-actin and nucleolin. D4-GDI
(rho GDP dissociation inhibitor 2) was also depicted as one of these caspase-sub-
strates and extensive experimental effort was made to pinpoint the acting caspase in
vivo. Using the caspase-3 specific inhibitor Z-DEVD-fmk it was shown that D4-GDI is
being cleaved by active caspase-3 in cultured apoptotic BJAB cells. This result was
confirmed in cell free extracts using the caspase-3 specific substrate Ac-DEVD-pNA as
a competitive inhibitor and by immunochemical depletion of procaspase-3, both lead-
ing to decreases of D4-GDI cleavage. Because D4-GDI is also reported to serve as
substrate for caspase-1, activation of caspase-1 upon drug treatment of BJAB/mock
cells was investigated. Western blot analysis showed no increase in concentration of
the mature subunit p20 of caspase-1. Additionally, in a caspase activity assay using the
caspase-1 specific substrate Ac-WEHD-pNA no significant cleavage activity could be
detected. Finally, mass spectrometric analysis of the resulting D4-GDI fragment clearly
showed that caspase-3 and not caspase-1 is responsible for cleavage of D4-GDI after
drug treatment of BJAB cells. The peptide containing the caspase-1 cleavage site was
also detected in the apoptosis-associated fragment of D4-GDI. Moreover, it is demon-
strated that apoptotic cell death bears no consequences for Rho-GDI 1, a protein which
displays high homology to D4-GDI, thereby providing evidence that cleavage of cellular
proteins during apoptosis is highly specific. 
However, the results from 2DE PAGE analysis indicated that the applied methodology
is not sufficient to detect changes of regulatory factors on protein level after drug-treat-
ment of BJAB/mock cells. Significant changes in protein concentration could only be
detected for caspase substrates. Therefore, some analytical efforts were made to over-
come this problem. For this purpose, sample preparation was designed in a more spe-8
cific way. Annexin V-coupled magnetic beads were used to separate apoptotic from
non-apoptotic cells. This method enriches apoptotic cells by binding to posphati-
dylserine (PS) which is exposed to the outer membrane upon induction of apoptosis.
However, exposure of PS appears to be a late event in drug-induced apoptosis of
BJAB/mock cells. Thus, this method did not lead to the identification of regulatory pro-
teins during apoptotic cell death. The fact that cleavage of caspase substrates was al-
ready detected in PS-negative cells further substantiates the finding that PS exposure
is a late event in BJAB cells undergoing apoptosis.
In another attempt, the visualisation technique was sensitized by metabolic radioactive
labeling (35S-methionine and 35S-cysteine) of proteins. By this method, detection limits
are lowered and changes in a specific time frame can be monitored. Results obtained
so far clearly indicate that metabolic labeling is suitable for detection of regulatory pro-
teins but inherits other difficulties: in most cases the amount of regulatory proteins is
far below the limit of mass spectrometric analysis and identification. In experiments
performed so far, one spot displaying considerable variation in intensity was detected
on images of 2DE PAGE gels derived from metabolic labeled samples but its identifi-
cation was not yet successful.9
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Indices II INDICES
I-1 ABBREVIATIONS
°C degree Celsius
µ micro (x 10-6)
2DE PAGE two-dimensional polyacrylamide gel electrophoresis
A ampere(s)
aa amino acid(s)
ACN acetonitrile
AIF apoptosis inducing factor
Apaf apoptosis associated factor
APS ammoniumperoxodisulfate
CAD caspase activated DNase
CAPS 3-cyclohexylamino-1-propanesulfonic acid
CARD caspase recruitment domain
caspase cysteinyl aspartate-specific protease
CHAPS 3-(3-cholamidopropyl)dimethylammonio-1-propane sulfonate
cyt c cytochrome c
Da Dalton
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Foreword IIII FOREWORD
Life
the state of a material complex or individual characterized
by the capacity to perform certain functional activities,
including metabolism, growth, reproduction, and some
form of responsiveness and adaptation. Life is further char-
acterized by the presence of complex transformations of
organic molecules and by the organization of such mole-
cules into the successively larger units of protoplasm, cells,
organs, and organisms.
This is the definition given in the Encyclopaedia Britannica. Just as there is a definition
for life there is one for
Death 
the total cessation of life processes that eventually occurs
in all living organisms. The state of human death has
always been obscured by mystery and superstition, and its
precise definition remains controversial, differing accord-
ing to culture and legal systems.
The present work neither deals with life nor with death in particular but it deals with the
transition from life to death in certain circumstances. Although a vast amount of work
has been devoted since the late 19th century to discover how cells multiply the study
of cell death is of relatively recent concern. This theme first appeared in the Index Med-
icus - an index to medical literature - in 1979.
Definition: although the general meaning of in vitro is ’outside a living body’ within this study the intention
is slightly different and shall be understood as ’outside a living cell’ (after destruction of the plasma mem-
brane). Consequently experiments carried out with cell free extracts are called in vitro experiments. Ex-
periments performed in cultured cells in contrast are referred to as ’in vivo’ experiments.18
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III-1 APOPTOSIS
III-1.1 EARLY DISCOVERIES
In 1890 William Councilman visualized cell death in humans for the first time (Council-
man, 1890). He described vacuolated acidophilic bodies in liver tissue from yellow fe-
ver patients. But despite the observation of similar acidophilic bodies in other types of
liver damage it took about 70 years and the use of electron microscopy to reveal that
Councilmans acidophilic bodies were dying and/or dead cells (Kerr, 1969, Kerr, 1971).
In parallel, it was shown that these cell death morphologies were not unique to liver
damage but also occurred in the normal developing mouse during fusion of the palate
(Farbman, 1968). Following these studies Kerr and colleagues published a detailed de-
scription of morphological changes associated with this form of cell death and called it
apoptosis (Kerr, 1972). In the past several years it became clear that the observed mor-
phological changes during cell death are determined by the activity of a group of cys-
teinyl proteases known as caspases (Alnemri et al., 1996). 
III-1.2 ULTRASTRUCTURAL PHENOMENONS
Early ultrastructural features of apoptosis are the disintegration of cell junctions and
condensation of the cytoplasm. The cells shrink and no swelling is observed as in the
case of necrosis. At the surface of the nucleus lumps of chromatin aggregate, the nu-
clear membrane develops folds, and the nucleus splits into a number of membrane-
bound, ultrastructurally well-preserved fragments. These fragments are shed and
promptly taken up by specialized scavenger cells or even by ordinary, neighboring
cells. The nuclear changes seem to be energy-dependent; they may reflect the fact that
genes in the nucleus are beginning to express themselves in new ways, in response to
unknown stimuli. 
III-1.3 APOPTOSIS OVERVIEW
Apoptosis, also called programmed cell death, is a mechanism that allows cells to self-
destruct when stimulated by an appropriate trigger. This program is activated for vari-
ous reasons, e.g. when the cell is no longer needed within the body or when it becomes
a threat to the health of the organism. Apoptosis is implicated in a variety of biological
systems, such as embryonic development, differentiation, tissue homeostasis and de-
fense against pathogens. Aberrant inhibition or initiation of apoptosis contributes to
many diseases, including cancer. Basically, apoptosis is a normal physiological pro-
cess that offets cell proliferation. Proteins involved in this process are evolutionarily
conserved and homology is found ranging from the nematode Caernorhabditis elegans19
Introduction III(C. elegans) to man. The apoptotic machinery can be activated from inside (e.g. p53
signalling) or outside the cell (e.g. via death receptors) and further regulation is
achieved by involvement of proteins of the BCL-2 family. The center of the apoptotic
executive machinery is constituted by a family of cysteinyl proteases, termed caspases
(cysteinyl aspartate-specific protease).
III-1.4 FROM NEMATODE TO MAN
Core components of the apoptotic machinery have been discovered in the C. elegans
model system. Genetic studies identified three genes which are indispensable for re-
moval of exactly 131 among 1090 somatic cells during development: the genes CED-
3, CED-4 and CED-9 (Banda et al., 1992; Ellis et al., 1991; Laurent-Crawford et al.,
1991). The protein encoded by CED-3 (CED-3) is an effector of programmed cell death
located most downstream in the cascade of the three proteins and the mammalian ho-
mologs are caspases. The CED-9 protein (CED-9) represents an inhibitor of cell death
in the nematode and is the prototypic member of the growing family of cell death regu-
lators, the BCL-2 protein family. The CED-4 gene product (CED-4) is located in be-
tween CED-3 and CED-9 and APAF-1 was identified as the mammalian counterpart
(Zou, 1997, Chinnaiyan, 1997). 
III-2 CASPASES: THE CENTRAL EXECUTIONERS OF APOPTOSIS
The first caspase was initially discovered as a cytokine-processing enzyme and desig-
nated interleukin-1β converting enzyme (Cerretti, 1992, Yuan, 1993). The presence of
the conserved pentapeptide sequences QACR(N/Q)G at the caspase active site
(Thornberry, 1998) and the rapid expansion of the expressed sequence tag (EST) da-
tabase led to the identification of over 14 caspases in a short period of time (Fig. 1).
Caspase-1 and -11 have been shown to function mainly in cytokine processing (Li,
1995, Kuida, 1995, Wang, 1998) whereas caspase-2, -3, -6, -7, -8, -9, -10 and -12 are
involved in the regulation and execution of apoptosis (Kuida, 1996, Hakem, 1998, Var-
folomeev, 1998, Begeron, 1998, Nakagawa, 2000). As the number of cloned caspases
increases and since the human genome became sequenced, more proteins related to
the caspases are being identified with divergence even at the highly conserved pen-
tapeptide active site e.g.: caspase-homologue 1 (CSP-1) (Shaham, 1998) and DREDD
caspase (Chen, 1998). 
Caspases are synthesized as zymogens with the general organization shown in Fig. 2.
(Cohen, 1997). An N-terminal prodomain is followed by sequences encoding a large
and a small subunit. In some caspases the subunits are separated by a small spacer.
This spacer is excised from the zymogen during maturation. All cleavages involved in
the activation of procaspases occur at the carboxyl side of aspartate residues (Earn-
shaw, 1999) and the only known eukaryotic proteases with this specificity are the20
Introduction IIIcaspases themselves and the cytotoxic T lymphocyte serine protease granzyme B
(Greenberg, 1996, Pham, 1997, Thornberry, 1997). Caspase prodomains range in
length from 23 amino acids (aa) for caspase-6 and -7 to 219 aa for caspase-10.
Caspases with large prodomains are thought to be involved in the initiation of the apo-
ptotic response (initiator caspases) and those harbouring a short prodomain are appar-
ently activated in a first step by the initiator caspases followed by a second
autoproteolytic step. These are therefore called effector caspases. On the basis of se-
quence alignments and functional studies two related motifs in the N-terminal region of
initiator caspases have been discovered: the death effector domain (DED) (Chinnaiy-
an, 1995) and the caspase recruitment domain (CARD) (Hofmann, 1997). The DED is
found in caspase-8 and 10 and is necessary for interaction of these caspases with
adaptor proteins like FADD (Fas associated protein with death domain) (Chinnaiyan,
1995, Boldin et al., 1995) and TRADD (tumor necrosis factor associated protein with
DD) (Hsu, 1995) in receptor mediated induction of apoptosis. The CARD is found in
caspase-1, -2, -4 and -9 and was shown to be involved in promoting interactions of
these caspases with one another and with other regulatory and adaptor proteins, e.g.
APAF-1 (Brakebusch et al., 1992, Tartaglia, 1993, Takahashi et al., 1996, Itoh, 1993).  
Not only the length and structure of the prodomain defines the position of a caspase in
the protease cascade, but the caspases display distinct intracellular localization (Zhi-
votovsky, 1999) which sometimes changes after activation. Zhivotovsky et al. found
that in Jurkat cells procaspase-2 is distributed throughout the cytosol, microsomes and
mitochondria, procaspase-3 and -9 are located in the cytosol and mitochondria where-
as procaspase-7 and -8 were detected exclusively in the cytosol. After induction of ap-
optosis the localization of active caspases was different: caspase-2 was found only in
the nuclei and caspase-3 was detected in cytosolic, mitochondrial and nuclear frac-
tions. The authors further report the redistribution of caspase-7 (pro- and active form)
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Caspases 6, 4 and 1 are related to cytokine response and caspases 3, 6 and 7 are activated down-
stream of initiator caspase-8, -10, -9 and -2. Caspase-14 is not included and still under investigation. 21
Introduction IIIto the microsomal fraction, whereas active caspase-8 was predominantly present in the
cytosol and to a minor extent in microsomal, mitochondrial and nuclear fractions. Active
subunits of caspase-9 were cytosolic and probably associated with mitochondria. 
III-3 CELL DEATH PATHWAYS   
Three main starting points of apoptosis are known; these are controled by death recep-
tors, mitochondria and, as published recently, the endoplasmic reticulum (Nakagawa,
2000). Although much effort has been made concerning death receptor signalling as
well as initiation of the apoptotic cascade by mitochondria, still tremendous investiga-
tion has to be made to elucidate the precise mode of action of these different pathways
to death. Furthermore, there is an ongoing debate about potential cross-talk of different
pathways. Nevertheless, parallel mechanisms of induction, execution and regulation of
differentially triggered pathways are likely to exist (see Fig. 3)
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Fig. 2: Caspase structure. Although caspases belong to one family of enzymes they strongly
differ in sequences of their prodomains. This reflects different signalling pathways of activation.
Active caspases consist of two large and small subunits. The active site is formed by two different
subunits from two different molecules as indicated by a flash.22
Introduction IIIIII-3.1 EXTERNAL TRIGGERS: DEATH RECEPTORS
The interaction of surface receptors with their cognate ligands is a fine-tuned mecha-
nism to rapidly and selectively regulate life and death of a cell in higher organisms. Sev-
eral receptors are capable of transmitting cytotoxic signals into the cytoplasm although
many of these receptors display a wide range of apoptosis unrelated functions (e.g. cell
activation, differentiation and proliferation). Moreover it is highly cell type specific
whether the given signal leads to rapid cell death or proliferation. This is well document-
ed for tumor necrosis factor (TNF) which exerts a costimulatory effect on naive lympho-
cytes and induces death signals in activated lymphocytes. The TNF-receptors (TNF-R)
belong to an emerging family of receptors, the TNF receptor superfamily, with impor-
tant function in differentiation, survival and cell death and for some members of this su-
perfamily apoptosis inducing activity has been reported (Schulze-Osthoff, 1998).
One subgroup of TNF-R is characterized by the presence of a common death domain
(DD. Itoh, 1993; Tartaglia, 1993) and therefore referred to as death receptors (DRs).
Members of this subfamily are TNF-R1, CD95/Fas/APO-1, TRAMP/DR3/APO-3,
TRAIL-R1/DR4/APO-2, TRAIL-R2/DR5, DcR1/TRAIL-R3 and DcR2/TRAIL-R4. DcR1
lacks the intracellular domian (Pan et al., 1997, MacFarlane et al., 1997, Sheridan et
al., 1997) and DcR2 contains a truncated non-functional DD (Mongkolsapaya et al.,
1998, Degli-Esposti et al., 1997, Degli-Esposti et al., 1997, Marsters et al., 1997). Re-
ceptor oligomerization upon ligand binding mediates transmission of the cytotoxic sig-
nal into the cytoplasm via the DDs. As an example, CD95-signalling is depicted in Fig.
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Introduction III4. The formation of the death inducing signalling complex (DISC) in CD95-induced ap-
optosis relies on FasL-(or other crosslinking agents) mediated receptor trimerisation
and recruitment of adaptor molecules. 
These adaptor molecules consist of a DD, necessary for interaction with the cytoplas-
matic receptor DD, and further a domain displaying the ability to associate with pro-
caspases, the death effector domain (DED). The FADD DED was identified by transient
expression of the N-terminal region of FADD (Chinnaiyan, 1995), which is sufficient to
cause apoptosis. In contrast, overexpression of the C-terminal part, containing the DD,
lacking the DED, protects the cell from receptor mediated apoptosis. This C-terminal
deleted protein functions as a dominant negative mutant FADD (FADDdn). The finding
that overexpression of inactive FADD or procaspase-8 (see Fig. 4) did not only block
CD95 but also TNF-R1 signalling (Boldin et al., 1996, Chinnaiyan et al., 1996), al-
though FADD does not bind to TNF-R1, led to the identification of TRADD (TNF-recep-
tor associated protein with death domain). TRADD mediates binding of FADD after
engagement of TNF-R1 thereby inducing procaspase-8 activation. Another pathway of
CD95 may involve activation of procaspase-2 through RIP-interacting protein (RAIDD)
(Duan and Dixit, 1997) reasoning that RAIDD contains a DD and a CARD domain, that
is also present in caspase-2 (Schulze-Osthoff, 1998). 
Besides apoptosis-mediating adaptor molecules harbouring a DED there are also neg-
procaspase-3
caspase-3
procaspase-8
caspase-8
CA
RDDD
pro
ca
sp
as
e-2
caspase-2
D
D
D
DD
D
RAIDD
CD95
D
D
FADD
DED
DISC
Fig. 4: CD95-signalling. After trimerisation of the receptor adaptor molecules are recruited (e.g. FADD,
RAIDD) and mediate binding of procaspases. Close proximity induces autoactivation of the procaspas-
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Introduction IIIative regulatory elements containing this domain. These caspase-8 (former flice) inhib-
itory proteins (FLIPs) are known from several herpes viruses and molluscipox virus
(Thome et al., 1997) and contain two DEDs. Two cellular FLIPs are known so far, FLIPL
and FLIPS, which both display significant antiapoptotic activity by incorporation into the
DISC. Although FLIPL has sequence similarity to caspase-8, it blocks autoproteolytic
activation of procaspase-8 when incorportated into the DISC due to replacement of the
caspase-8 active site cysteine by a tyrosine in FLIPL, rendering it proteolytically inac-
tive (Irmler, 1997).
III-3.2 INTERNAL TRIGGER: MITOCHONDRIA
Even cells without a mitochondrial genome (ρ0 cells) can die by apoptosis (Jacobson,
1993). Consequently, for some time, mitochondria were thought not to play a role in the
execution process of the apoptotic program. This assumption was underscored by the
finding that the anti-apoptotic protein BCL-2, which resides in the outer mitochondrial
membrane, still prevented death in these cells.
However, mitochondria are believed today to be a key component of the apoptotic ma-
chinery. It has been shown that in cell free extracts caspase activation by APAF-1 re-
quires cytochrome c and dATP (Liu, 1996). APAF-1 contains an amino-terminal CED-
3-like domain with a caspase recruitment domain (CARD), a central CED-4-like domain
and a carboxyterminal stretch of 13 WD-40 repeats. WD-40 repeats mediate the inter-
action of proteins and are supposed to be the binding site for cytochrome c (Srinivasu-
la, 1998). Multimerization of APAF-1, cytochrome c and dATP induces a
conformational change in APAF-1 thereby exposing its CARD and mediating recruite-
ment of procaspase-9. This multimolecular complex consisting of APAF-1, cytochrome
c and dATP is called mitochondrial death inducing signalling complex (DISC). Pro-
caspase-9 is recruited to the DISC by interaction of its prodomain with the APAF-1
CARD domain and activation is then achieved by autoprocessing induced by the prox-
imity of the procaspase molecules (Kuida, 2000, Srinivasula, 1998). The stochiometry
of the mitochondrial DISC is still under investigation. Interestingly, another CARD-pro-
tein, ARC (apoptosis repressor with CARD), has been identified in skeletal muscle and
heart which ineracts with procaspase-8 and procaspase-2 but not procaspase-9 (Ko-
seki et al., 1998). This indicates cross talk between CD95/Fas and mitochondrial death
inducing signalling pathways. Two possible models that could explain the apotosis in-
hibitory function of ARC are discussed: repression of apoptosis by ARC might be
caused by inhibition of caspase activation via direct binding to the death proteases or
ARC could inhibit processed mature caspases. 
Cytochrome c release from the intermembrane space is followed by mitochondrial per-
meability shift, ion flux and, in accordance with the acidic pH optimum of caspases,
acidification of the cytoplasm (Matsuyama et al., 2000). Another protein liberated from25
Introduction IIImitochondria is the apoptosis inducing factor (AIF). This molecule translocates to the
nucleus and mediates caspase-independent DNA fragmentation (Susin et al., 1999,
Daugas et al., 2000) into large fragments, a process which is different from the activity
of caspase activated DNase (CAD). CAD is constitutively inhibited by the inhibitor of
CAD (ICAD), which is cleaved by active caspase-3; the complex then dissolves and
CAD executes its DNase activity (Enari et al., 1998). This is in agreement with the find-
ings that in some cells apoptosis is changed to a more necrotic phenotype by addition
of caspase inhibitors (McCarthy et al., 1997).
 
In addition to these findings the opening of mitochondrial permeability transition (PT)
pores is suggested to be the root mechanism for the release of apoptogenic proteins
(Vander Heiden, 2000) from mitochondrial intermembrane space. The adenine nucle-
otide translocase (ANT), the voltage dependent anion channel (VDAC) and cyclophilin
D (cyP D) are the basic units of the PT pore (Crompton, 1999) and the complex is lo-
cated at contact sites between the mitochondrial inner and outermembrane. PT pore
opening leads to matrix swelling and outermembrane rupture which in turn is reasoned
to be the cause of cytochrome c and AIF release (Zamzami et al., 1995)
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Introduction IIIIII-3.3 INTERNAL TRIGGER: ENDOPLASMIC RETICULUM
The contribution of the endoplasmic reticulum (ER) to apoptosis has only recently been
discovered in mice. The initiator caspase in this pathway is caspase-12 which resides
in the ER membrane directed to the cytosol and belongs to the caspase-1 subfamily.
Activation of caspase-12 is triggered by ER stress in general which means inhibition of
protein transport or inhibition of N-glycosylation or disruption of Ca2+ homeostasis in
particular.  Experiments in caspase-12 knock out mice indicate that activation  of
caspase-12 is independent from death receptor signalling and mitochondrial targeted
apoptotic signals but essential for ER-stress induced apoptosis (Nakagawa, 2000).
III-3.4 REGULATORS OF APOPTOSIS: BCL-2 FAMILY PROTEINS
The proteins of the BCL-2 family play a pivotal role in the regulation of apoptosis. All
members contain at least one of four conserved domains which are present in the pro-
totypic BCL-2 protein and therefore are called BCL-2 homology (BH) domains (BH1,
BH2, BH3, BH4). The family of BCL-2 proteins can be subdivided into pro- and antiap-
optotic proteins. The latter, BCL-2, BL-xL and BCL-w, possess all four BH domains,
and MCL-1 and A1 posses at least the BH1 and BH2 domain. Both, BH1 and BH2, are
necessary to bind to and thereby inhibit the proapoptotic activity of BAX (Yin, 1994,
Chittenden, 1995, Sedlack, 1997). In contrast, the proapoptotic proteins BAX, BAK and
BOK lack the BH4 domain and the proteins BID, BAD, BIK, HRK and BIM are charac-
terized by the presence of a BH3 domain only. Although the BH3 domain is necessary
for bak and BID to bind to BCL-xL and promote cell death, the proapoptotic activity of
this domain is not always dependent on its ability to interact with antiapoptotic proteins
(Wang, 1996). Proapoptotic signalling of BCL-2 family proteins is regulated by het-
erodimerization of pro- and antiapoptotic proteins (e.g. BAX / BCL-2) and/or a confor-
mational change in the complexed proapoptotic protein induced by another cell death
promoting family member. Heterodimerization is not required for prosurvival signalling
(Cheng, 1996, Kelekar, 1997). 
The proapoptotic activity of BID is mediated by induction of a conformational change in
BAX and translocation of BAX to the outer mitochondrial membrane followed by di- or
oligomerization (Eskes, 1999, Desagher, 1999). This can also be the reason for re-
lease of cytochrome c and other apoptosis related proteins from the inter membrane
space, because BAX, BCL-2 and BCL-xL bear the potential to form channels at least
in lipid bilayers (Antonsson et al., 1997, Green, 1998, Minn, 1997). Emphasis to the
pore forming capability of BCL-xL is given by the close spatial proximity of BH1, BH2
and BH3, creating an elongated hydrophobic cleft. This structure bears significant sim-
ilarities to the pore forming domains of several bacterial toxins (colchicins A, E1 and
diphteria toxin (Antonsson et al., 1997, Minn, 1997, Schendel et al., 1997, Schlesinger
et al., 1997).27
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Further prosurvival activity of BCL-2 and BCL-x is mediated by regulation of the VDAC,
which resides in the outer mitochondrial membrane. Both proteins have been shown to
interact with VDAC and thereby maintain exchange of complex anions between cytosol
and inter-membrane space of mitochondria (Vander Heiden, 2000) and prevent re-
lease of cytochrome c (Shimizu, 2000). In contrast, the proapoptotic activity of BH3-
only proteins is reported to induce cytochrome c release wthout permeability transition
(Shimizu, 2000).
III-3.5 CASPASE SUBSTRATES
Several protein substrates of caspases have been reported and some well character-
ized ones are summarised here. 
The probably best characterized caspase substrate is PARP (poly-ADP ribose poly-
merase) which is cleaved early during apoptosis in many systems (Kaufmann, 1989;
Kaufmann et al., 1993). PARP (116 kDa) is cleaved to a 24 kDa and a 89 kDa fragment
representing the N-terminal DNA-binding domain and the C-terminal catalytic subunit,
respectively. PARP is an ATP-dependent DNA repair enzyme, and specific cleavage
during apoptosis abrogates both, its DNA repair (Casciola-Rosen et al., 1996) and AT-
Pase activity. Caspase-7 and caspase-3 seem to be responsible for PARP degradation
(Lazebnik et al., 1994, Cohen, 1997).
Proteolysis of lamins during apoptosis is supposed to be executed by caspase-6 as
caspase-6 cleaves lamin A after the specific sequence VEID (Orth et al., 1996, Taka-
hashi et al., 1996). This sequence is located in a well conserved α-helical rod domain
and cleavage may result in disruption of lamin-lamin interaction followed by some of
BCL-2, BCL-xL,
BCL-w, A1BH2BH1BH4 BH3 TM
BH4 BH3 TM
BH2BH1BH3 TM
BH2BH1BH3
BH3 TM
BH3
P
L
R
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ligand domainL:
formation of 
hydrophobic cleft
(receptor domain)
R:
BAX, BAK, 
BOK
BAD
BCL-xS
BID
BIK, BIML, 
HRK
BH2BH1BH3 TM MCL-1
regulation
Fig. 6: BCL-2 family proteins. The gross protein domain structure (not in scale) for some BCL-2 relat-
ed proteins. TM: membrane insertion domain according to Adams and Cory (1998) and Kroemer (1997).28
Introduction IIIthe characteristic nuclear changes during apoptosis (Ucker et al., 1992, Oberhammer
et al., 1994, Lazebnik et al., 1995, Greidinger et al., 1996).
U1-70kDa is cleaved specifically during apoptosis, and the RNA-binding domain is sep-
arated from the arginine-rich region (Casciola-Rosen et al., 1996, Tewari, 1995). This
event is most likely mediated by caspase-3 and separating the domains of the enzyme
from one another may have a dominant-negative effect on U1-70kDa activity resulting
in blockade of splicing and probably influencing cellular repair pathways which rely on
new mRNA synthesis (Cohen, 1997).
Protein kinase C δ (PKCδ) is cleaved by caspase-3 but not caspase-1, -4 and -6 (Cas-
ciola-Rosen et al., 1996, Song et al., 1996) to form an catalytically active fragment.
Overexpression of an active PKCδ fragment is associated with chromatine condensa-
tion indicating that proteolytic activation of PKCδ contributes to some features of the
apoptotic phenotype (Emoto et al., 1995, Ghayur et al., 1996).
An important mediator of cell cycle progression, the retino blastoma protein (Rb), is
also proteolytically cleaved during apoptosis (Janicke et al., 1996, Browne et al., 1994,
An and Dou, 1996). Rb is relevant for cell cycle progression after phosphorylation by
cyclin-dependent kinases and an anti-apoptotic function has been reported
(Kouzarides, 1995). Different sized cleavage products can be observed probably dis-
playing cleavage activity of different caspases. The cleavage product produced after
proteolysis at an DEAD motif fails to bind the regulatory protein MDM2 (Janicke et al.,
1996).
In addition, numerous downstream substrates of caspases have been identified, many
of these being involved in DNA repair, RNA maturation or maintainance of structural
integrity.
III-3.6 CASPASE INHIBITORS
Viral and Cellular Caspase Inhibitors
For an infected cell the far most effective way to prevent viral replication is to kill itself.
Since apoptosis is used to defend against viruses, some viruses carry cell death inhib-
itors to block this response of their host cells. Several viral cell death inhibitors act by
binding to activated caspases.
The cowpox virus encodes the cytokine response modifier A (crmA) which inhibits
caspase-1, thereby reducing the defensive inflammatory response triggered by IL-1β
(McFadden, 1995). Moreover, it was found that crmA prevents defensive suicide of in-
fected cells thereby providing more time for viral replication (Ray, 1996). This also
stressed the close proximity of inflammatory response and apoptosis. With respect to
the inhibitory constants it can be stated that crmA inhibits active caspase-1 and
caspase-8 (Los, 1995, Tewari, 1995, Varfolomeev, 1998) and is unlikely to inhibit
caspase-3, -6 and -7 in vivo (Zhou et al., 1997, Garcia-Calvo, 1998). Besides the fact29
Introduction IIIthat it inhibits caspase-9 with a Ki of 2 nM (compared to 0.3 nM for caspase-8) it is stat-
ed that it cannot inhibit caspase-9 in vivo.(Kuida, 1998, Smith, 1996).CrmA belongs to
the family of serine proteases, the pseudosubstrate residues are LVAD and after cleav-
age polypeptides are released. 
The baculoviral p35 not only blocks apoptotic response to infections in insect cells but
is in addition capable of inhibiting the C. elegans CED-3 protein and caspase-1, -3, -6,
-7, -8 and -10 (Ki < 10 nM; Bump et al., 1995, Zhou, 1998). P35 neither inhibits non-
caspase cysteinyl proteases nor serine proteases. In contrast to crmA the cleaved sub-
units of p35 remain in an inhibitory complex that can be dissolved by SDS (Zhou, 1998).
Inhibitor of apoptosis proteins (IAPs) were first identified in baculoviruses (Clem, 1991,
Clem, 1994). Up to now, six human IAP relatives have been identified: NAIP, cIAP1,
cIAP2, XIAP, survivin and apollon (Deveraux, 1998, Chen, 1999) and at least cIAP1,
cIAP2 and XIAP have been shown to directly inhibit caspase activity. IAPs share a
common structural motif which is called the baculoviral IAP repeat (BIR). The BIR-do-
main is a cysteine- and histidine-rich sequence motif of 70 aa length and has been
shown to bind to and inhibit caspases (Deveraux et al., 1997, Roy et al., 1997, Dever-
aux, 1998, Takahashi et al., 1998). XIAP inhibits caspase-8-induced protease acticity
at the level of caspase-3 and caspase-7 whereas cytochrome c induced activation is
additionaly prevented upstream of the effector caspases by direct inhibition of caspase-
9 processing. 
Synthetic Caspase Inhibitors
A number of specific caspase inhibitors have been developed based on the substrate
cleavage sites of prefered substrates or a combinatorial approach (see table 1) to find
optimum peptide sequences of the different caspases. These inhibitors act as pseu-
dosubstrates for active caspases and are therefore competitive inhibitors. Most widely
used are specific tetrapeptide inhibitors but also trimers, especially with the sequence
VAD, are applied for certain purposes. Specific inhibitors resemble the structure Z-P4-
P3-P2-D-end (Z = benzyloxycarbonyl-). The end-group varies according to the purpose
of the tetrapeptide. As end-groups for caspase substrates mostly chromophors are
used, especially pNA (para-nitroanilid) and AMC (aminomethylcoumarin) as colorimet-
ric and fluorometric substrates, respectively. Caspase inhibitors are capped with fluo-
romethylketone (fmk) or chloromethylketone (cmk). Those groups produce irreversible
inhibitors because a thiomethylketone is formed with the active site cysteine of the
caspase resulting in inactivation of the enzyme. In experiments with cultured cells the
fmk group should be prefered because of superior membrane permeability (Ekert,
1999)30
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Different substrate specificity allows to subdivide caspases into three groups. Despite
the absolute requirement for D in the P1 position caspase-1, -4 and -5 display a prefer-
ence for hydrophobic amino acids at the P4-position. The second subgroup consists of
caspase-2, -3, -7 and CED-3, these enzymes show specificity for aspartate in the P4
position and the general motif is represented by DEXD. At last, for caspase-6, -8 and -
9 comprise the third subgroup and for their proteolytic activity the common cleavage
sequence is (L/V)EXD.
Table 1: Preferred sequence specificity of caspases. . 
Caspase Optimal Sequence (P4P3P2P1)
caspase-1 WEHD
caspase-4 (W/L)EHD
caspase-5 (W/L)EHD
C. elegans CED-3 DETD
caspase-3 DEVD
caspase-7 DEVD
caspase-2 DEHD
caspase-6 VEHD
caspas-8 LETD
caspase-9 LEHD31
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III-4.1 TAXOL
The cytotoxicity of taxol is based on its ability to alter the formation of microtubuli. In
contrast to vincaalcaloids, which inhibit tubulin polymerisation, taxol enhances forma-
tion of microtubuli (Horwitz, 1992, Nicolaou, 1994, Pazdur, 1993). Microtubuli play an
important role during mitosis: the cytoskeleton breaks down and the mitotic spindle ap-
paratus is build of the tubulin pool. Upon taxol treatment, microtubuli differ from physi-
ologically constituted polymers: they show a decreased diameter, consist of 12 instead
of 13 profilaments and are shorter in length. Furthermore, they are more resistant to
depolymerisation by decreased temperature or increased Ca2+ concentration. Taxol
operates in all phases of the cell cycle. During mitosis star-shaped microtubuli forma-
tion is observed and in other cell cycle phases microtubuli bundles are formed. Isolation
of tubulin in stable structures consequently blocks formation of the mitotic spindle-ap-
paratus (Schiff and Horwitz, 1979, Horwitz et al., 1994).
III-4.2 EPIRUBICIN
Epirubicin most effectively influences exponentially growing cells in the S- and G2-
phase of the cell cycle. The mechanism of epirubicin treatment is not yet fully under-
stood but includs intercalation into DNA and non-covalent binding to DNA, inhibition of
topoisomerases (topo) I and II and other helicases and production of reactive oxygen
species (ROS) (Chan et al., 1996). Intercalation seems to play a minor role in cancer
therapy because high concentrations of epirubicin are required for this effect and are
not achieved under therapeutic treatment conditions. Topo II mediates alteration of the
three dimensional structure in condensed DNA and inhibition of this enzyme results in
persisting strand-breaks. Topo II-inhibitors bind to the DNA-topo II-complex and inhibit
re-ligation of the single strands by formation of an irreversible, ternary complex (Ross,
1978, Ross, 1981, Tewey, 1984).32
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Two major cell-intrinsic pathways have been demonstrated over the past five years to
induce apoptosis. One pathway starts with death receptor ligation and the other in-
volves cytochrome c release from mitochondria. Cytostatic drug-induced apoptosis has
been reported to be mediated by induction of death receptor ligand expression (Friesen
et al., 1996, Friesen et al., 1997, Müller et al., 1997, Fulda et al., 1997, Fulda et al.,
1998). However, other groups announced that chemotherapeutic drugs induce apop-
tosis independent of CD95/Fas signalling, exclusively via the mitochondrial apoptotic
pathway (McGahon et al., 1998, Adjei et al., 1998, Eischen et al., 1997, Micheau et al.,
1999). Therefore, it is still a matter of debate how cytostatic drugs induce apoptosis,
and whether cytostatic drug-induced apoptosis is mediated via the CD95/Fas pathway
or is independent of death receptor signalling. 
Thus, the aim of this study was the analysis of cytostatic drug-induced apoptosis in the
human B-lymphoid cell line BJAB. Two different cytostatic drugs, taxol and epirubicin,
were chosen for examination of their effects on cultured BJAB cells. These drugs target
different cellular molecules and therefore provide a more general answer to the mode
of action of cytostatic drugs. The goal was to investigate which apoptotic cascade(s) is
(are) initiated, and especially the order in which caspases are activated in this experi-
mental setup had to be determined. Furthermore, the question whether the results ob-
tained in BJAB cells as a model system represent a general principle of cytostatic drug-
induced apoptosis was addressed. For this NALM6 and REH B-lymphoid cell lines
were examined to provide evidence for a general statement on the mechanisms in-
volved in cytostatic drug-induced apoptosis in B cells. 
Anitbodies against various apoptosis-related proteins can be used to answer most of
these questions. However, this approach is not suitable to reveal yet unknown proteins
involved in cytostatic drug-induced apoptosis. In order to investigate general effects of
cytostatic drug-treatment on protein level, two-dimensional polyacrylamide gelelectro-
phoresis (2DE PAGE) had to be performed to detect apoptosis-associated proteins.
Identification of specific caspase substrates could give clues to downstream effects of
caspase activation and elucidate consequences of protease activation during apopto-
sis in more detail. Furthermore, regulatory proteins acting upstream of caspase activa-
tion can eventually be detected by 2DE PAGE. 33
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V-1 CHEMICALS AND REAGENTS
Table 2: Chemicals and Reagents. All reagents used were p.a. grade.  
Substance Supplier
3-(cyclohexylamino)-propane-1-sulphonic acid 
(CAPS)
SIGMA, München, Germany
35S-Methionine/cysteine labeling mix Amersham Buchler, Braunschweig, Germany
40% acrylamide/bisacrylamide 29:1 Roth GmbH & Co, Karlsruhe, Germany
Acetonitril (ACN), HPLC grade MERCK, Berlin, Germany
Acrylamide Carl Roth GmbH & Co, Karlsruhe, Germany
Agarose BioRad, München, Germany
Ammoniumperoxodisulfate (APS) Carl Roth GmbH & Co, Karlsruhe, Germany
3-[(3-Cholamidopropyl)dimethyl-ammonio]-1-
propanesulfonate (CHAPS)
SIGMA, München, Germany
Coomassie Brilliant Blue R-250 Carl Roth GmbH & Co, Karlsruhe, Germany
dATP SIGMA, München, Germany
Dithiothreitol (DTT) SIGMA, München, Germany
epirubicin Pharmacia Upjohn, Erlangen, Germany
Ethanol Carl Roth GmbH & Co, Karlsruhe, Germany
Ethylendiamine tetra acetic acid (EDTA) Carl Roth GmbH & Co, Karlsruhe, Germany
Fetal Calf Serum Life Technologies GmbH, Karlsruhe, Germany
HCOOH, 37% stock Carl Roth GmbH & Co, Karlsruhe, Germany
N-[2-hydroxyethyl]piperazine-N`-[2-ethane-
sulfonic acid] (HEPES)
Carl Roth GmbH & Co, Karlsruhe, Germany
IEF gel solution WITA, Teltow, Germany
Leupeptin SIGMA, München, Germany
L-Glutamine Life Technologies GmbH, Karlsruhe, Germany
Methanol Carl Roth GmbH & Co, Karlsruhe, Germany
MgCl2 Carl Roth GmbH & Co, Karlsruhe, Germany
Nitrocellulose membrane Schleicher & Schüll, Dassel, Germany
Non fat dry milk powder Glücksklee
Penicillin/Streptomycin Life Technologies GmbH, Karlsruhe, Germany
Phenyl-methyl-sulfonyl-fluoride (PMSF) SIGMA, München, Germany
Ponceau-S SIGMA, München, Germany34
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V-3 ENZYMES AND PROTEINS
Cytochrome c: SIGMA, München, Germany
RNase A: Carl Roth GmbH & Co, Karlsruhe, Germany
Trypsin: Promega, Mannheim, Germany
Bovine Serum Albumin (BSA):SIGMA, München, Germany, 
Potassium chloride (KCl) Carl Roth GmbH & Co, Karlsruhe, Germany
Propidium iodide (PI) Carl Roth GmbH & Co, Karlsruhe, Germany
Protein-A Sepharose SIGMA, München, Germany
RPMI 1640 Life Technologies GmbH, Karlsruhe, Germany
SDS-PAGE gel solution WITA, Teltow, Germany
Sodium chloride (NaCl) Carl Roth GmbH & Co, Karlsruhe, Germany
Sodium dodecylsulfate (SDS) Carl Roth GmbH & Co, Karlsruhe, Germany
Sucrose Carl Roth GmbH & Co, Karlsruhe, Germany
taxol (paclitaxel) Bristol Arzneimittel, München, Germany
Tris-(hydroxymethyl)-amino-methane (TRIS) Carl Roth GmbH & Co, Karlsruhe, Germany
Triton X-100 Carl Roth GmbH & Co, Karlsruhe, Germany
Tween 20 Carl Roth GmbH & Co, Karlsruhe, Germany
Table 3: Cell lines. 
cell line description
BJAB Burkitt like lymphoma cell line transfectants BJAB/mock, BJAB/crmA 
and BJAB/FADDdn were kindly provided by Dr. Klaus Schulze-Osthoff, 
University of Tübingen, Tübingen, Germany
NALM6 human B-cell lymphoma cell line
REH human B-cell lymphoma cell line
Table 2: Chemicals and Reagents. All reagents used were p.a. grade.  
Substance Supplier35
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Z-DEVD-fmk, Z-WEHD-fmk: irreversible, cell permeable specific caspase inhibitors
were from Kamyia Biomedical company, Seattle, WA, USA.
Ac-DEVD-pA, Ac-IETD-pNA:specific colorimetric caspase substrates were purchased
from Calbiochem-Novabiochem GmbH, Bad Soden, Germany.
5,5´,6,6´-tetrachloro-1,1´,3,3´-tetraethyl-benzimidazolylcarbocyanin iodide (JC-1):was
purchased from Molecular Probes, Leiden, The Netherlands.
V-5 ANTIBODIES
Secondary antibodies, anti-mouse and anti-rabbit, coupled to horse radish peroxidase
were purchased from Promega, Mannheim, Germany. Anti-goat antibody coupled to
horse-radish peroxidase was purchased from Santa Cruz, California, USA .
V-6 KITS
Table 4: Primary antibodies. 
antibody directed against description
caspase-1 polyclonal rabbit; # sc-622; Santa Cruz, California, USA
caspase-1 p20 subunit polyclonal goat; # sc-1780; Santa Cruz, California, USA
caspase-3 polyclonal rabbit; # 65906E; Pharmingen, Hamburg, Germany
caspase-8 monoclonal mouse; kindly provided by Dr. Klaus Schulze-Osthoff, 
University of Tübingen, Tübingen, Germany
caspase-9 polyclonal rabbit; # 68086E; Pharmingen, Hamburg, Germany
rho-GDI/D4-GDI polyclonal rabbit; # 66586E; Pharmingen, Hamburg, Germany
PARP polyclonal rabbit; # 65196E; Pharmingen, Hamburg, Germany
Bicinchonic assay (Pierce) KMF Laborchemie Handels GmbH, 
St. Augustin, Germany
Enhanced chemoluminescence 
(ECL)
Amersham Buchler, Braunschweig, Germany36
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VI-1 CENTRIFUGATION (GENERAL COMMENT)
If not otherwise mentioned cells are harvested by centrifugation at 300 x g at 4°C for 5
min. This corresponds to 2500 rpm in an Eppendorf centrifuge and 1200 rpm in a Vari-
fuge 3.0R (Heraeus). Cells were handled on ice if no further treatment or growing was
intended.
VI-2 CELL CULTURE
Human Burkitt Like Lymphoma cells, BJAB, stably transfected with crmA, FADDdn or
vector control (pcDNA 3) were kindly provided by Klaus Schulze Osthoff (University of
Tübingen, Tübingen, Germany). Cells were maintained in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal calf serum, 100 U/mL penicillin, 100 µg/mL
streptomycin and 0.56 g/L L-glutamine and incubated at 37°C in 95% air and 5% CO2.
Cells were subcultured every 3-4 days by dilution of the cells to a concentration of 1 x
105 cells / mL. NALM6 and REH cells were cultured under the same conditions as
BJAB cells.
VI-3 INDUCTION OF APOPTOSIS
VI-3.1 CELL CULTURE
Cells were grown in RPMI 1640 supplemented with 10% (v/v) fetal calf serum (FCS),
0.56 g/L L-glutamine, 100 000 i.u. penicillin and 0.1 g/L streptomycin. Cells were sub-
cultured every 4 days by dilution of the cells to a concentration of 1x105 /mL.
VI-3.2 CYTOSTATIC DRUG TREATMENT
Cells were seeded at a density of 4x105 /mL 24 hs prior to starting an experiment. For
induction of apoptosis cells were then harvested and resuspended at a density of 1x105
cells/mL with the desired concentrations of the respective cytostatic drugs. In standard
experiments taxol and epirubicin were used at a concentration of 0.12 µM and 1.85 µM,
respectively.
VI-3.3 INHIBITOR EXPERIMENTS
For inhibition of caspase activity, cells were incubated with different irreversible, cell
permeable peptide inhibitors at various concentrations. 
1. Z-DEVD-fmk (inhibitor of caspase-3-like activity)
2. Z-WEHD-fmk (inhibitor of caspase-1-like activity)37
Methods VIStock solutions of the inhibitors were prepared in DMSO or EtOH as indicated and
stored at 4°C. Inhibitors were added to the cell culture 2 hs prior to treatment with cy-
tostatic drugs, and control cultures containing the same concentration of DMSO or
EtOH, respectively were grown in parallel. 
VI-4 QUANTIFICATION OF APOPTOTIC CELLS
VI-4.1 TRYPAN BLUE EXCLUSION 
Cells were harvested at 400 x g for 5 min and incubated with Trypan blue solution for
5 min. Blue cells were assumed as dead. The number of living and dead cells was as-
sessed by counting in a Neubauer counting chamber. At least 100 cells were counted.
VI-4.2 MODIFIED CELL CYCLE ANALYSIS
After treatment, cells were spun down at 300 x g for 5 min. and resuspended in cold
PBS. Cells were then fixed in PBS/2% H2CO (v/v) on ice for 30 min. and spun down
again. After fixation, cells were incubated with 66 % EtOH in PBS for 15 min. on ice or
at -20°C over night. RNA was digested after further centrifugation by addition of 50 µL
of PBS containing 40 µg/mL RNase and incubation at 37°C for 30 min. Then, cells were
pelleted again and DNA was stained by addition of 200 µL of propidium iodide (50 µg/
mL) in PBS. 
Percentage of hypodiploid cells was assessed by flow cytometric analysis (Nicoletti et
al., 1991) using a FACScan (Becton Dickinson, Heidelberg, Germany) equipped with
CELLQuest software. Apoptotic cells were determined by quantitating the sub-G1 peak
using the analysis software mentioned above.
VI-4.3 DEPOLARISATION OF MITOCHONDRIA (JC-1 ASSAY)
Cells were harvested, washed in PBS and then collected by centrifugation at 300 x g.
1 x 105 cells were resuspended in RPMI 1640 without phenol red and supplements
(glutamine, penicillin, streptomycin) with or without 2.5 µg/mL 5,5´,6,6´-tetrachloro-
1,1´,3,3´-tetraethyl-benzimidazolylcarbocyanin iodide (JC-1). Samples were incubated
for 30 min. at 37°C with shaking. After centrifugation at 300 x g, 4°C for 5 min. cells
were first washed, resuspended in 200 µL ice-cold PBS and analysed immediately by
flow cytometry. Cells with decreased fluorescence compared with untreated control
cells were assumed to display lower mitochondrial membrane potential. Data were col-
lected on a FACScan and quantification was performed using the CELLQuest software.38
Methods VIVI-5 IN VITRO INDUCTION OF MITOCHONDRIAL APOPTOTIC CASCADE
Cell extracts were prepared as decribed (Deveraux et al., 1997). After harvesting, cells
were washed twice in PBS and once in buffer H, spun down again and cells were incu-
bated in buffer H (containing 100 µM PMSF) on ice for 15 min.. Rupture of membranes
was achieved by passing the cells through a 0.80 mm x 0.40 mm needle 15 times. The
suspension was cleared by centrifugation at 16000 x g twice for 15 min. at 4°C. Clear
supernatants were used for in vitro activation of mitochondrial apoptotic cascade or to
determine inherent caspase activity. Mimicry of mitochondrial induction of apoptosis (in
vitro caspase activation)  was achieved by addition of 1 mM DTT, 1 µM horse heart cy-
tochrome c and 1 mM dATP and incubation at 30°C for 5 min. followed by incubation
at 37°C for different periods of time. Control extracts were likewise incubated in the ab-
sence of cytochrome c and dATP.
VI-6 CLEAVAGE OF CASPASE SPECIFIC COLORIMETRIC SUBSTRATES
Cell extracts were prepared as described above, and protein concentration was deter-
mined using the BCA assay kit. 10 µL of extract were mixed with 90 µL of buffer B. Just
prior to measurement of absorption at 405 nm 2 µL of colorimetric substrate were add-
ed.  Samples were incubated at 37°C and absorption values were determined after ap-
propriate periods of time according to the speed of absorption increase. Specific
caspase activity was calculated from the extinction values and the protein concentra-
tion of the extract.
VI-7 SAMPLE PREPARATION FOR GEL ELECTROPHORESIS
The sample preparation was different according to the purpose of the analysis. In gen-
eral, cell pellets and protein solutions were handled at 4°C to avoid protein degradation.
Nevertheless, buffers always contained a protease inhibitor mix, either PMSF/pepsta-
tin/leupeptin or the protease inhibitor cocktail from Boehringer. 
Buffer H
20 mM HEPES, pH 7.0
10 mM KCl
2 mM MgCl2
1 mM EDTA
Buffer B
50 mM HEPES, pH 7.4
100 mM NaCl
1 mM EDTA
0.1 % CHAPS
10 % saccharose
5 mM DTT39
Methods VIVI-8 ONE DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS
VI-8.1 PREPARATION OF SDS-PAGE GELS
According to the apparent molecular weight of the proteins in question, gels containing
different concentrations of acrylamide were used. The composition of different gels is
given in table 5. Separation was performed at 200 V until the methylene blue front had
left the gel’s end. 
VI-8.2 SAMPLE PREPARATION FOR ONE DIMENSIONAL GEL ELECTROPHORESIS
Cells were treated with the respective cytostatic drugs or left untreated. After incuba-
tion, cells were harvested at 300 x g for 5 min. and washed twice in an appropriate vol-
ume of PBS. After washing, lysis was achieved by addition of buffer L and using a
Vortex for 30 s. Debris was spun down at 16000 x g for 15 min and the supernatant
was collected an used as sample.
VI-8.3 DETERMINATION OF PROTEIN CONCENTRATION
Protein concentration was determined using the BCA assay kit from Pierce according
to the manufacturer’s protocol. 2 - 5 µL of sample were diluted in 200 µL of BCA solu-
tion in an ELISA plate (flat bottom) and incubated at 37°C for 30 min. in the dark.  Ab-
sorption was measured using an ELISA reader at 590 nm. BSA was used as standard
and the protein concentration was calculatied on the basis of the derived standard
curve.
Table 5: Composition of polyacrylamide gels. 10% aqueous APS was prepared freshly 
and the acrylamide stock solution contained acrylamide/bisacrylamide in a ratio of 29:1. 
stacking acrylamide(40%) / mL
Tris/Cl (0.5 M)
pH 6.8 / mL
H2O
/ mL
SDS (10%)
/ µL
TEMED
/ µL
APS (10%)
/ µL
4 % 0.375 0.380 2.185 30 3 3
running Acrylamide(40%) / mL
Tris/Cl (1.5 M)
pH 8.5 / mL
H2O
/ mL
SDS (10%)
/ µL
TEMED
/ µL
APS (10%)
/ µL
8 % 2.0 2.5 5.3 100 8 100
10 % 2.5 2.5 4.7 100 4 100
12 % 3.0 2.5 4.3 100 4 100
16 % 4.0 2.5 3.3 100 4 100
Buffer L
10 mM Tris/Cl, pH 7.5
300 mM NaCl
1 % Tritin-X 100
2 mM MgCl2
5 mM EDTA
1 µM pepstatin
1 µM leupeptin
100 µM PMSF40
Methods VIVI-9 HIGH RESOLUTION TWO DIMENSIONAL PAGE GEL ELECTROPHORESIS
VI-9.1 PREPARATION OF FIRST DIMENSION PAGE GELS (ISOLELCTRIC FOCUSING GELS)
For preparation of IEF rod gels, premixed acrylamide solutions from WITA GmbH (Tel-
tow, Germany) were used. Solutions were thawed and degassed for 15 min. using a
water-jet pump. 25 µL of 0.8 % APS were added to 975 µL acrylamide solution, mixed
gently and the liquid was pulled in either 0.9 mm diameter or 1.5 mm diameter glass
capillaries of 23 cm length fastened in a gel casting apparatus. The designated volume
in the capillaries was left empty to allow sample application and addition of cap-gel so-
lution respectively. After polymerisation (30 min.) capillaries were turned upside down,
cap-gel solution (390 µL) was also degassed and 10 µL of 0.8 % APS were added. The
solution was mixed gently and filled into the upper end of the capillary using a tubercu-
line syringe.
After 15 min. of incubation, water resulting from polymerisation was removed. Capping
ends of the capillaries were overlayed with water. The openings at the sample end of
the capillaries were covered with a water droplet and both ends were closed with para-
film. Gels were used after 3 days of polymerisation in the dark at room temperature.
VI-9.2 PREPARATION OF SECOND DIMENSION PAGE GELS (SDS-PAGE GELS)
For this purpose, WITA gel solutions were used which are delivered in 73.5 mL ali-
quots. After thawing the desired amount of acrylamide solution (1 aliquot per gel of 0.9
mm ∅ , 3 aliquots per 2 gels of 1.5 mm ∅) 1.28 % APS (5 mL per aliquot) was added
and the solution was mixed gently. Glas plates were fixed in the appropriate gel casting
apparatus and 40 % glycerol (aqueous solution) was filled between the glass plates at
the bottom, acrylamide solution was poured into from the top. Filled plates were cov-
ered with parafilm. After 30 min. of polymerisation, casted gels were turned upside
down, the glycerol was removed and the top was covered with buffer P and parafilm.
Gels were stored at 4°C overnight and ready to use the following day.
Separating gel solution Cap-gel solution
3.5 % acrylamide 12 % acrylamide
0.3 % piperazine diacrylamide 0.13 % piperazine diacryl-
amide
9 M urea 9 M urea
4 % WITAlyte 4 % WITAlyte
5 % glycerol 5 % glycerol
0.06 % TEMED 0.06 % TEMED
Buffer P
285 mM Tris base
90 mM Tris/Cl
3.5 mM SDS41
Methods VIVI-9.3 SAMPLE PREPARATION FOR TWO DIMENSIONAL GEL ELECTROPHORESIS
For subtractive analysis of 2DE PAGE gels, high reproducibility is essential and sample
preparation is the most crucial step in 2DE PAGE. When subtractive analysis was de-
sired sample preparation was performed in parallel.
In general, cells were harvested in the same manner as for one dimensional gel elec-
trophoresis. After washing in PBS the weight of the pellet was determined (=W / mg)
and lysis was achieved by addition of 1.08 x W mg urea. Resulting volume (=V) was
assumed to be 2 x W and sulfide bonds were reduced by addition of  0.05 x V DTT (1.4
M stock solution, 70 mM final concentration). Sample was supplemented with 2 % Ser-
valyte (pH 2-4) and protease activity abolished with PMSF (1 mM final concentration,
200 mM stock in ethanol) and pepstatin (1 µg/mL final concentration, 100 µg/mL stock).
The resulting suspension was mixed using a Vortex for about 15 min. at room temper-
ature. DNA was separated by centrifugation in special tube at 100,000 x g for 20 min
at 4°C and the supernatant was collected as protein sample and stored at -80°C. 
VI-9.4 ISOELECTRIC FOCUSING (FIRST DIMENSION)
Water was removed from both ends of the IEF gels, the bottom end filled with buffer K
and gels were set up in the IEF apparatus. Sample ends were covered with 5 mm
sephadex solution and the sample applied on top of it (10 µL for 0.9 mm diameter rod
gels, 20-30 µL for 1.5 mm diameter rod gels). Sample was covered carefully with 5 µL
overlay solution and buffer A filled on top of it. Buffer K was filled onto the bottom of the
apparatus and buffer A into the top reservoir so that the gel tops were covered. Electric
current program is given in table 6. 
After finishing isoelectric focusing, gels were pressed onto a special tray using a sy-
ringe equipped with a 200 µL pipet tip filled with buffer I. Gels were equilibrated in buffer
I two times 5 min. and stored at -80°C until use.
Buffer K (degassed) Buffer A (degassed)
9 M urea 3 M urea
5 % ethylendiamine ortho-phosphoric acid
5 % gylcerol
Sephadex solution Overlay solution
100 µL sephadex solution 5.3 µL urea
108 mg urea 5 mg Servalyte pH 2-4
10 µL ampholytes pH 2-11 0.7 µL glycine
Buffer I (no pH adjustment!)
285 mM Tris base
90 mM Tris/Cl
3.5 mM SDS42
Methods VI 
VI-9.5 SDS-PAGE (SECOND DIMENSION)
The covering solution was removed from the gels’ top slits and IEF gels were placed
on top. Rod gels were fixed with 1 % buffer AG. Second dimension gels were placed
into the running apparatus filled with SDS-PAGE buffer. Bromphenol blue solution was
added to the top reservoir (kathodic reservoir) and separation was performed at 11°C
for 5-7 hs. Running conditions were as given in table 7. 
Table 6: Electric current program for IEF. Gels were run at room temperature for 21 hs 15 
min using the indicated program on a BioRad Power Pack 3000. 
U/Volt time
100 1 h
200 1 h
400 17.5 hs
650 1 h
1000 30 min.
1500 10 min.
2000 5 min
Buffer AG
1 % agarose
0.1 % SDS
125 mM Tris pH 6.8 
(adjusted with H3PO4)
SDS PAGE Buffer
25 mM Tris base
129 mM glycine
0.1 % SDS
Table 7: Electric current programs for second dimension SDS-PAGE gels. Protein sepa-
ration was performed at 11°C for 5-7 hs and stopped at the time when bromphenol blue front
reached the indicated gel end (1 cm prior to the end of glass plates).
I/mA time I/mA time
65 15 min. 120 15 min.
85 5 - 7 hs 160 5 - 7 hs
0.9 mm thickness 1.5 mm thickness43
Methods VIVI-9.6 SDS-PAGE GEL STAINING
After two dimensional gel electrophoresis, gels were stained with respect to the pur-
pose of the gels. Analytical gels (in general 0.9 mm gels) were stained using the pro-
tocol of Heuckeshofen and Dernik (Heuckeshofen and Dernick, 1985), preparative gels
(1.5 mm) were either stained with Coomassie Brilliant Blue or silver stained according
to the protocol of Blum et al. (BLUM ET AL., 1987). All gels were fixed in fixing solution
for at least 2 hs or over night prior to staining. If blotting was desired, gels were left un-
fixed and proteins were transferred to the membrane immediately after finishing sec-
ond dimension protein separation.
VI-9.7 SILVER STAIN (ANALYTICAL, HEUCKESHOFEN AND DERNICK, 1985)
Gels were fixed over night at 4°C or room temperature with shaking in fixation solution,
incubated in incubation solution for 1 h with shaking and equilibrated in water (3 times
20 min.). Proteins were stained by application of staining solution for 30 min. and gels
were rinsed in water (30 s). Subsequently, the staining pattern was visualised using de-
veloper solution (3 - 7 min.). After removal of the developer solution, reaction was
stopped with stop solution.
VI-9.8 COOMASSIE BRILLIANT BLUE STAINING (CBB STAINING)
After fixation, gels were incubated in CBB staining solution over night and then
destained by several changes in destaining solution until a satisfactory staining pattern
was observed. Gels were stored at 4°C in a plastic bag.
Fixation solution
5 % acetic acid
50 % ethanol
Incubation solution Staining solution
0.5 M NaAc 0.2 % AgNO3
0.1 M Na2S2O3 0.01 % CH2O (37% stock)
1.25 % glutaraldehyde
30 % ethanol
Developer solution Stop solution
240 mM Na2CO3 100 mM EDTA
0.01 % CH2O (37% stock)
CBB-staining solution Destaining solution
0.1 % CBB R-250 5 % acetic acid
10 % acetic acid 50 % ethanol
50 % ethanol44
Methods VIVI-9.9 SILVER STAIN (PREPARATIVE, BLUM ET AL., 1987)
This method was applied to gels desired for spot identification since the method applied
to analytical 2DE PAGE gels wasn’t adequate (proteins are permanently fixed in the
acrylamide matrix due to the reaction with glutaraldehyde). 
The gels were fixed and subsequently the acid was removed by stepwise washing with
30% ethanol (20 min.) and water (20 min.). Sensitation was accomplished by applying
0.02 % Na2S2O3 solution for about 1 min and sodium thiosulfate solution was discard-
ed and gels rinsed two times with water. Gels were equilibrated in staining solution for
45 min., rinsed two times in water and proteins were visualized by application of devel-
oper solution until a satisfying spot intensity was reached. Reaction was stopped with
stop solution and the gels were stored in a plastic bag at 4°C.
VI-10 BLOTTING 
Blotting was performed using a BioRad semi dry blotting apparatus (Transblot SD cell).
Membranes and filter paper were swollen in CAPS buffer for several minutes and the
blotting sandwich consisted of (anode) 3 x filter paper, NC membrane, SDS-PAGE gel,
3 x filter paper (kathode). The size of the filter papers and the membrane fitted exactly
the gel’s size. Blotting was performed at 1 mA / cm2 for 45 min. - 75 min. in regard to
percentage of the acrylamide in the gel and the molecular mass of the protein(s) in
question. Membranes were stained with Ponceau Red to verify homogenous  protein
transfer and destained in H2O. Membranes were dryed and stored at room temperature
in a plastic bag.
VI-11 IMMUNOCHEMICAL DEPLETION OF CASPASE-3
Caspase-3 was immunoprecipitated from cellular extracts of BJAB cells as described
(Geilen et al., 1997). Briefly, 100 µl of cellular extract were incubated with 0.5 mg of
protein A-Sepharose and 20 µl (4 µg) of polyclonal rabbit anti-human caspase-3 anti-
body at 4°C for 4 hs with moderate shaking. The protein A-Sepharose immune complex
was sedimented by centrifugation at 300 g, 4°C for 5 min. The cleared supernatant was
used for in vitro activation by addition of dATP and cytochrome c as described above.
Control extracts were prepared in parallel in the presence of protein A sepharose but
in the absence of antibody.
10xCAPS
100 mM CAPS; pH 11
Blotting buffer
10 mM CAPS
10 % MeOH45
Methods VIVI-12 IDENTIFICATION OF PROTEINS
VI-12.1 IMMUNOCHEMICAL IDENTIFICATION
Immunodetection of protein was performed as described (Wieder et al., 1994). Mem-
branes were blocked for one hour in blocking buffer using either non-fat dry milk pow-
der or casein as blocking reagent. The first antibody was diluted in blocking buffer and
applied for one hour at room temperature with moderate shaking in a 15 cm diameter
petri dish. Then, membranes were briefly washed in PBST and incubated in PBST
twice for 10 min.. Secondary antibody was diluted in PBST and applied for one hour at
room temperature with shaking. Excess antibody was washed away with PBST and
membranes were again shaken in PBST twice for 10 min.. Freshly prepared enhanced
chemoluminescence (ECL) solution was applied for 2 min. and membranes were dried
between filter paper. After positioning the membranes in the cassette (aligned to one
edge) films (also aligned to the same edge) were exposed to the membranes for differ-
ent periods of time to obtain optimal results. Processed images were identically posi-
tioned in the film box and marker bands were marked on the films.
VI-12.2 MASS SPECTROMETRIC IDENTIFICATION
Tryptic In-Gel Digest of Coomassie Stained Gel Pieces
Spots were cut from two dimensional PAGE gels and equilibrated in an appropriate vol-
ume of coomassie destaining buffer for 30 min. at 30°C with shaking. Buffer was dis-
carded and when necessary the wash was repeated. Gel pieces were then nearly dried
10xPBST
10 x PBS
0.5 % Tween 20
Blocking Buffer 
1 x PBST
10
3
%
or
%
blocking reagent
non-fat dry milk powder
Equilibration buffer
200 mM Tris/Cl, pH 8.5
Digestion buffer
100 mM Tris/Cl, pH 8.2
1 mM Ca2Cl
Coomassie destaining buffer
Equilibration buffer : ACN 1:146
Methods VIin a SpeedVac (5-10 min.) and digestion was achieved by addition of 0.1-0.2 µg trypsin
in an appropriate volume of digestion buffer. Digest was performed at 37°C with shak-
ing over night. Reaction was stopped by addition of 10 % trifluoroacetic acid to give a
final concentration of 2 % - 3 % and shaking at 60 °C for 20 min.
Tryptic In-Gel Digest of Silver Stained Gel Pieces
Destaining of spots was achieved by incubation in reducing buffer until brownish color
was removed completely. Gel pieces were equilibrated in plenty of water. Water was
changed several times to assure complete removal of the chemical agents.
Preparation of Samples for Mass Spectrometry
After tryptic digest supernatant was collected and peptides were further eluted from gel
pieces by shaking in Tris/Cl, pH 8.5 : ACN 1:1 for 20 min at 37°C. Supernatant was col-
lected, ACN evaporated by centrifugation in a SpeedVac for 20 min. and peptides re-
suspended in 0.1 % TFA aqueous solution. Then peptides were collected on a Zip Tip
by pipetting the solution several times through the Tip. Peptides were eluted from the
Tip with max. 5 µL elution buffer and ACN again was evaporated in a SpeedVac. Pep-
tides were resuspended in 60 % MeOH, 1 % HCOOH. Alternatively after binding to the
Zip Tip, peptides were eluted directly with 60 % MeOH, 1 % HCOOH.
VI-13 ANNEXIN-V BASED CELL FRACTIONATION
BJAB/mock cells were treated with 0.12 µM taxol or 1.85 µM epirubicin for 48 hs and
fractionation was performed according to the manufacturers’ protocol. Briefly, approx-
imately 1 x 107 cells were resuspended in 80 µL and 20 µL of a suspension of Annexin-
V coupled microbeads were added. After incubation at 4°C, cells were washed in 1 mL
of binding buffer and applied to a positive selection column in the presence of a mag-
netic field, equilibrated in 3 mL Annexin-V binding buffer. PS-negative cells which
passed through the column were collected and the column was washed with 3 x 500
µL of binding buffer. The column was removed from the magnetic field and PS-positive
cells were eluted in 1000 µL Annexin-V binding buffer using the supplied plunger to
flush the cells out. Collected cells were spun down at 300 x g and the resulting pellet
was used for further investigation.
Reducing buffer (prepared freshly)
15 mM ferricyanide (30 mM stock)
50 mM Na2S2O3  (50 mM stock)
Elution buffer
60 % acetonitril (ACN)
0.1 % TFA47
Methods VIVI-14 METABOLIC 35S-LABELING
Cells were starved in methionine/cysteine free RPMI 1640 medium for 2 hs at a density
of 4 x 105 cells/mL. Then, 35S-labeled methionine/cysteine labeling mix and cytostatic
drugs or labeling mix alone were added (50 µCi/mL). Cells were cultured for 6 hs - 12
hs. Then, the cells were harvested by centrifugation at 300 x g, washed in 1 x PBS and
the resulting pellet was used as sample. 48
Results VIIVII RESULTS
VII-1 CYTOSTATIC DRUG TREATMENT OF BJAB CELLS
In a first set of experiments, BJAB/mock cells were incubated with different concentra-
tions of taxol or epirubicin for different periods of time. Mock transfected BJAB cells
(BJAB/mock) were used as control. The range of tested concentrations was 0.012 µM
to 1.2 µM for taxol and 0.19 µM to 18.5 µM for epirubicin and time of incubation was 24
hs, 48 hs, 72 hs and 96 hs. It turned out that 0.12 µM taxol and 1.85 µM epirubicin ef-
ficiently induced apoptosis after 72 hs of treatment (60 - 70 %) and these drug concen-
trations were therefore used as standard concentrations. 
VII-1.1 CELL DEATH UPON TREATMENT WITH CYTOSTATIC DRUGS
To examine cytostatic drug-induced cell death and growth inhibition, cells were incu-
bated in the presence or absence of 0.12 µM taxol and 1.85 µM epirubicin. Induction
of cell death was confirmed by trypan blue exclusion. As shown in Fig. 7, populations
of treated cells and cells left untreated diverged from one another. While cell death in-
creased upon treatment with taxol or epirubicin and reached 70 % it was below 10 %
in control populations.
Epirubicin treatment stopped cell growth within 24 hs, number of total cells decreased
and number of dead cells increased as the number of living cells decreased. This is
reflected by the increasing percentage of dead cells finally reaching about 70 % after
72 hs of incubation. Taxol treament caused comparable effects but inhibition of cell
growth was somewhat delayed. Percentage of dead cells was about 60 % after 72 hs
of treatment with taxol (Fig. 7). 
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Fig. 7: Drug-induced cell death. The number of dead cells was determined using trypan blue exclu-
sion. Blue cells were assumed to be dead and unstained cells scored as living. Bars display percent-
age of dead cells (right axis). Cell numbers are indicated at the left axis. Total cell number = dead
(stained) cells + living (unstained) cells.49
Results VIIVII-1.2 DNA FRAGMENTATION
To distinguish between necrotic and apoptotic cell death, a modified cell cycle analysis
was performed. This method is suitable to detect DNA content of cells by staining fixed
cells with propidium iodide (PI) and thereby discriminating between cells in different
phases of cell cycle: G0/1, G2/M and hypodiploid cells. Because apoptosis results in
DNA strand breaks (Earnshaw, 1999) upon activation of DNA digesting enzymes, e.g.
CAD (Enari et al., 1998), this method can be used to determine the number and per-
centage of apoptotic cells in a cell population. The results of a representative time-
course experiment are shown in Fig. 8. The number of apoptotic cells increased with
time of incubation and reached about 60 % after 72 hs in both taxol- and epirubicin-
treated cell populations thereby confirming the data obtained by trypan blue exclusion. 
VII-1.3 CLEAVAGE OF PARP
Poly-(ADP-ribose)-polymerase, a 116 kDa protein located in the nucleus, is a typical
substrate of caspase- 3 and cleaved during apoptosis resulting in the formation of a 84
kDa and a 32 kDa fragment (Wieder et al., 1997). As the detection of hypodiploid cells
by FACS analysis indicated cell death via apoptosis rather than necrosis this protein
was chosen as a marker protein for apoptosis. SDS PAGE was performed using a 10
% polyacrylamide gel and Western blot analysis with an anti-PARP antibody (Ab) re-
vealed specific, time-dependent cleavage of PARP upon cytostatic drug treatment (Fig.
9)
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Fig. 8: Modified cell cycle analysis of drug-treated BJAB/mock cells. BJAB/mock cells were incu-
bated with taxol and epirubicin for 24 hs, 48 hs and 72 hsas depicted. Subsequently modified cell cycle
analysis was performed. The number of hypodiploid cells is given as percent of 10000 events counted. 50
Results VII.
These experiments confirmed apoptotic cell death and further indicated activation of
caspase- 3 during drug induced apoptosis. Control samples did not show significant
cleavage of PARP.
VII-2 UNRAVELING THE APOPTOTIC SIGNALLING PATHWAY
VII-2.1 CASPASE-3
It is well known that a family of cysteinyl proteases, the so called caspases, is involved
in apoptotic cell death. Caspases are expressed as zymogens in many cells and acti-
vated by limited proteolysis to form active heterotetramers (Earnshaw, 1999). Thus, im-
munodetection of caspase subunits can be used to show processing and activation of
the zymogen. 
Detection of caspase-3 subunit (p17) was performed by Western blot analysis using a
polyclonal Ab specific for procaspase-3 and the mature p17 subunit. Fig. 10 shows that
the 17 kDa subunit, p17, of the active caspase-3 heterotetramer is formed upon treat-
ment of BJAB/mock cells with cytostatic drugs. Epirubicin-induced processing of
caspase-3 preceded taxol-induced effects and already reached its maximum after 24
hs. Taxol-induced formation of the p17 subunit reached its maximum after 48 hs. These
results clearly show that the cytostatic drugs taxol and epirubicin at the indicated con-
centration (0.12 µM and 1.85 µM; respectively)  induce apoptosis rather than necrosis.
fragment
PARP
control 0.12 µM taxol 1.85 µM epirubicin
24 hs 48 hs 72 hs 24 hs 48 hs 72 hs24 hs 48 hs 72 hs
Fig. 9: Cytostatic drugs induce cleavage of PARP. BJAB/mock cells were incubated with the indicat-
ed concentrations of cytostatic drugs for 24 hs, 48 hs and 72 hs. Western blot analysis revealed the spe-
cific cleavage of PARP. The full length PARP and the corresponding 84 kDa fragment are indicated at
the right margin.51
Results VII 
VII-2.2 CASPASE-9
As caspase-3 is the most prominent downstream effector caspase, drug induced
caspase-3 processing could happen via two differing signalling pathways: (I) death re-
ceptor mediated signalling via TNF-R superfamily or (II) activation of mitochondria. To
investigate these two possibilities, a pAb specific for caspase-9 (proenzyme and sub-
unit) was used. As caspase-9 is activated by  formation of a cytosolic complex consist-
ing of APAF-1, cytochrome c, dATP and caspase-9 (Li et al., 1997) after mitochondrial
permeability shift and release of cytochrome c (Bossy-Wetzel et al., 1998), detection of
caspase-9 subunits would indicate processing of caspase-3 via the mitochondrial sig-
nalling pathway. Results are shown in Fig. 11.
control 0.12 µM taxol 1.85 µM epirubicin
24 hs 48 hs 72 hs 24 hs 48 hs 72 hs24 hs 48 hs 72 hs
procaspase-3
17 kDa subunit
Fig. 10: Cytostatic drugs induce processing of caspase-3. BJAB/mock cells were incubated with
the indicated concentrations of cytostatic drugs for 24 hs, 48 hs and 72 hs. Western blot analysis shows
the specific processing of caspase-3 resulting in time-dependent appearance of the p17 subunit. The
positions of procaspase-3 and the 17 kDa subunit (p17) are indicated at the right margin.
control 0.12 µM taxol 1.85 µM epirubicin
24 hs 48 hs 72 hs 24 hs 48 hs 72 sh24 hs 48 hs 72 hs
procaspase-9
processed
caspase-9    pro
caspase-9
p20
Fig. 11: Cytostatic drugs induce processing of caspase-9. BJAB/mock cells were incubated with
the indicated concentrations of cytostatic drugs for 24 hs, 48 hs and 72 hs. Western blot analysis shows
the specific processing of caspase-9 resulting in time dependent appearance of the p20 subunit. The po-
sitions of procaspase-9 and the 20 kDa subunit (p20) are indicated at the right margin.52
Results VIIAs shown in Fig. 11, drug treatment of BJAB/mock cells led to processing of pro-
caspase-9 indicating that induction of the apoptotic cascade occurs via the mitochon-
drial signalling pathway. To confirm this by another methodology, flow cytometric
analysis of mitochondrial membrane potential was performed using the dye JC-1.
VII-2.3 DEPOLARISATION OF MITOCHONDRIA
The cationic carbocyanine dye JC-1 is a fluorescent marker for mitochondrial depolar-
ization during apoptosis. The most distinctive feature of JC-1 is its potential sensitive
emission color shift resulting in a decrease of the red/green fluorescence intensity ratio
in response to mitochondrial depolarisation. BJAB/mock cells were incubated either
with taxol or epirubicin or in control medium for different periods of time and FACS anal-
ysis was performed after staining mitochondria as described in the Methods section
(VI-4.3).
As shown in Fig. 12, depolarisation of mitochondrial membrane potential again in-
creased with time as did the above mentioned markers of apoptosis (PARP cleavage,
processing of caspase-3) after incubation with taxol or epirubicin. In contrast, control
samples didn’t show significant increase in mitochondrial depolarisation. Thus, activa-
tion of the mitochondrial apoptotic pathway seems to be an integrated part of the apo-
ptotic machinery after drug exposure of BJAB cells. 
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Fig. 12: Loss of mitochondrial membrane potential. BJAB/mock cells were incubated with the indi-
cated concentrations of cytostatic drugs for 24 hs, 48 hs and 72 hs. Then mitochondrial membrane po-
tential was analyzed by the JC-1 assay. Cells displaying decreased mitochondrial membrane potential
were scored as apoptotic. Results are given in % total of 10 000 events counted in FACS analysis.53
Results VIIVII-2.4 CASPASE-8
Detection of a drug-induced permeability shift of mitochondria and activation of
caspase-9 does not exclude the possibility of a parallel induction of the CD95/Fas sig-
nalling pathway. As caspase-8 is the initiator caspase in CD95/Fas signalling a mAb
detecting procaspase-8 and the processed forms of this enzyme (Bantel et al., 1999)
was used in Western blot analysis (Fig. 13). 
Surprisingly, not only the procaspase-8 content decreased but the concentration of the
18 kDa subunit, p18, of the active heterotetramer increased in a time dependent man-
ner after induction of apoptosis by taxol and epirubicin (see Fig. 13). However, the ap-
pearance of p18 was delayed in relation to caspase-3 activation rising the question
whether this cleavage of procaspase-8 was a consequence of caspase-3 activation.
VII-2.5 CASPASE-3 ACTIVITY ASSAY
As detection of the caspase-3 p17 subunit only indicates cleavage of the zymogen it
was also tested if this cleavage was accompanied by caspase-3 activation. In this ex-
periment the substrate Ac-DEVD-pNA was used to assay caspase-3-like cleavage ac-
tivity in extracts from BJAB/mock cells incubated with the respective cytostatic drugs
for 24 hs and 48 hs. The result is shown in Fig. 14: caspase-3 activity was clearly de-
tected and activation of the caspase was confirmed.
control 0.12 µM taxol
24 hs 48 hs 72 hs
1.85 µM epirubicin
24 hs 48 hs 72 hs24 hs 48 hs 72 hs
procaspase-8
processed forms
caspase-8   pro
p18 
subunit
Fig. 13: Caspase-8 processing after drug treatment. After treatment of BJAB/mock cells with the in-
dicated concentrations of taxol or epirubicin, protein samples (20 µg per lane) were separated by SDS
PAGE and subsequent Western blot analysis was performed using an Ab specific for procaspase 8 and
processed forms of caspase 8 (forms lacking the prodomain: ∆pro; active 18 kDa subunit: p18)54
Results VIIVII-3 CASPASE-8 AS INITIATOR OR SUBSTRATE?
The observation that the appearance of caspase-8 p18 subunit was delayed during in-
duction of apoptosis led to the assumption that caspase-8 may be activated down-
stream of caspase-3 to induce some kind of amplification of the apoptotic cascade
(Slee et al., 1999). This theory was reasonable because BJAB cells lack FasL mRNA
and FasL mRNA is not increased after cytostatic drug treatment (Daniel et al., 1997).
Thus, activation of caspase-8 via CD95/Fas signalling was unlikely to occur. 
VII-3.1 INHIBITOR EXPERIMENTS
The usage of the irreversible caspase-3 inhibitor Z-DEVD-fmk promised to answer the
question if caspase-8 is activated downstream of caspase-3. First BJAB/mock cells
were cultured in the presence of 0.12 µM taxol by addition of different concentrations
of Z-DEVD-fmk for 48 hs. The percentage of apoptotic cells was determined by flow
cytometric analysis (Fig. 15). Although it was not possible to completely block drug in-
duced apoptosis, Fig. 15 shows that addition of Z-DEVD-fmk clearly reduced the rate
of DNA fragmentation even at low concentrations <10 µM. Addition of the peptide in-
hibitor to cultured cells during incubation with cytostatic drugs led to a clear shift of the
17 kDa  subunit of caspase-3 to a higher apparent molecular weight of about 18 and
20 kDa, indicating that the inhibitor had irreversibly bound to the enzyme.
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Fig. 14: Ac-DEVD-pNA cleavage activity. BJAB/mock cells were incubated with or without cytostatic
drugs as indicated for 24 hs or 48 hs. Cellular extracts were prepared and the colorimetric substrate as-
say performed as described. Ac-DEVD-pNA cleavage activity was calculated on the basis of the absorp-
tion coefficient of pNA and normalized with respect to protein concentration.55
Results VII.
 Inhibition of caspase-3-like activity in this experimental setting was confirmed by West-
ern blot analysis of the cleavage of the caspase-3 substrate PARP, which was com-
pletely inhibited when drug-treated cells were incubated in the presence of the peptide
inhibitor (data not shown). In contrast to caspase-3, treatment of BJAB/mock cells with
Z-DEVD-fmk did not lead to a molecular weight upshift of the active subunit of caspase-
8, but completely blocked taxol- and epirubicin-induced processing of its proform (Fig.
16). 
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Fig. 15: Z-DEVD-fmk reduces the rate of taxol-induced apoptosis. BJAB/mock cells were incubat-
ed with 0.12 µM taxol for 48 hs in the presence of the indicated concentrations of Z-DEVD-fmk. Subse-
quently, cell cycle analysis was performed as described. Number of hypodiploid cells (apoptotic) is given
as percent of 10000 events counted in flow cytometric analysis.56
Results VII.
VII-3.2 TIME-DEPENDENT CASPASE-8 ACTIVITY INCREASE IN VITRO
To evaluate processing of caspase-8 upon induction of the mitochondrial apoptotic
cascade in vitro („in vitro activation“), cell extracts were prepared and the effects of cy-
tochrome c and dATP were studied. A time course experiment was performed in which
samples were incubated at 30°C in the presence of cytochrome c and dATP or kept at
room temperature. Caspase activities were measured in corresponding samples using
the peptide substrates Ac-DEVD-pNA and Ac-IETD-pNA (Fig. 17). Samples were also
analysed by Western blot analysis (Fig. 18) to correlate appearance of immunoreactive
bands to the caspase activities. 
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Fig. 16: Z-DEVD-fmk blocks drug-induced processing of caspase-8. Cells were cultured for 48 hs
with 0.12 µM taxol or 1.85 µM epirubicin in the presence or absence of 10 µM Z-DEVD-fmk. Caspase-3
and caspase-8 processing was examined by Western blot analysis (A) and specific apoptosis was de-
termined by assaying DNA fragmentation (B).57
Results VII.
VII-3.3 IMMUNOPRECIPITATION OF CASPASE-3 IN VITRO
Caspase-3 and Caspase-8 Activity Assay
To further confirm caspase-8 activation downstream of caspase-3, cell extracts from
control BJAB/mock cells were prepared as described. The sample was splitted.
Caspase-3 was immunoprecipitated by addition of caspase-3 Ab and protein A-
sepharose and incubation at 4°C with moderate rocking for 1 h. Control samples were
incubated in the presence of protein A-sepharose. Samples were splitted again and
positive controls were activated by addition of cytochrome c and dATP and incubation
at 30°C.
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Fig. 17: Caspase-3 and caspase-8-like cleavage activity after in vitro activation. As depicted mito-
chondrial caspase cascade was initiated by addition of cytochrome c and dATP and incubation at 30°C
for the indicated periods of time. Control samples were equally incubated without addition of cytochrome
c and dATP. Absorption resulting from specific cleavage of Ac-DEVD-pNA and Ac-IETD-pNA was deter-
mined and calculated as ∆E / min.
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Fig. 18: Caspase-8 processing after different periods of in vitro activation. Ident i ca l  samp les
used for determination of peptide substrate cleavage activity were examined by Western blot analysis
detecting caspase 8 pro- and processed forms. 58
Results VIIFollowing this, caspase-3-like activity was measured using the specific colorimetric
substrate, Ac-DEVD-pNA. As shown in Fig. 19, caspase-3 activity was diminished in
the caspase-3-depleted sample and reached only about 20 % of the activity measured
in the undepleted control sample. Samples were removed after different periods of in
vitro activation and Western blot analysis was performed to further examine caspase-
8 processing.
Western Blot Analysis of Caspase-8 Processing 
The same samples used to assay Z-DEVD-pNA cleavage activity after depletion of
caspase-3 were used for Western blot analysis. 15 µL of sample were separated by
SDS-PAGE and transfered to nitro-cellulose membrane. Caspase-8 detection was per-
formed as described using the suitable Ab. Fig. 20 shows that processing of pro-
caspase-8 was blocked in caspase-3-depleted extracts and can therefore be
considered as caspase-3-dependent in this experimental setup. 
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Fig. 19: Time course of Ac-DEVD-pNA cleavage.  Samples which had been treated as indicated
were examined on their ability to process Ac-DEVD-pNA by measuring absorption at 405 nm.59
Results VII 
Colorimetric Substrate of Caspase-3 as Inhibitor In Vitro
Since the idea of caspase-8 activation downstream of the effector caspase-3 is contro-
versally discussed additional experimental evidence for this phenomenon was neces-
sary. Therefore control extracts from BJAB/mock cells were prepared and splitted. To
investigate the role of active caspase-3 on caspase-8 processing in more detail, Z-
DEVD-pNA was added to the extracts just before and directly after activation with cy-
tochrome c and dATP. The colorimetric substrate was used instead of the irreversible
inhibitor Z-DEVD-fmk because it was possible to simultaneously monitor activation of
caspase-3 by measuring absorption. In this experimental setting, an excess of the pep-
tide substrate was used to investigate the effect of caspase-3 inhibition on cleavage of
caspase-8. As shown in  Fig. 21, caspase-3 processing is inhibited in samples taken
from this experiment after in vitro activation for up to 20 min. Interestingly, the appear-
ance of mature p17 is completely blocked in the presence of Ac-DEVD-pNA.
procaspase-8
processed
caspase-8    pro
p18 
subunit
0 10 20 40 70 130 190 0 10 20 40 70 130 190   t / min
Fig. 20: Caspase-8 activation in caspase-3-depleted cell extracts. Extracts were prepared and
caspase-3 was immunoprecipitated as described. After different periods of in vitro activation, samples
were examined by Western blot analysis.
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Fig. 21: Influence of Ac-DEVD-pNA on caspase-3 processing in vitro. The addition of Ac-DEVD-
pNA clearly delayed caspase-3 processing. This effect was stronger in samples which had been supple-
mented with Ac-DEVD-pNA prior to activation than in those which had been supplemented after activa-
tion.60
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Due to addition of the colorimetric substrate Ac-DEVD-pNA  processing of caspase-8
was delayed (Fig. 22). This confirmed that caspase-8 processing occurs downstream
of mitochondria and even downstream of caspase-3, at least in vitro.
VII-4 CYTOSTATIC DRUG TREATMENT OF BJAB/FADDDN CELLS
To further exclude an involvement of the CD95/Fas signalling pathway, BJAB cells sta-
bly transfected with a dominant-negative FADD mutant (FADDdn) were used. As the
adaptor molecule FADD recruits caspase-8 to the CD95/Fas signalling complex (death
inducing signalling complex, DISC (Chinnaiyan et al., 1996) after receptor trimerisation
and thereby induces caspase-8 processing and activation  this signalling pathway is
blocked in FADDdn transfectants. CD95/Fas-induced apoptosis was indeed shown to
be completely inhibited in BJAB/FADDdn cells (Bantel et al., 1999) and transfection
with FADDdn completely prevents caspase-3 activation upon triggering the cells with
agonistic anti-CD95 antibodies (Chinnaiyan et al., 1996). Activation of caspase-8 and
/ or caspase-3 in this cell type does therefore not occur upon induction of apoptosis via
CD95/Fas receptor trimerisation.
VII-4.1 DNA FRAGMENTATION IN CYTOSTATIC DRUG-TREATED BJAB/FADDDN CELLS
In a first set of experiments, drug-induced DNA fragmentation in BJAB/FADDdn cells
was assessed as compared with vector transfected BJAB/mock cells. Specific apopto-
sis was calculated by subtracting values obtained in control samples (spontaneous ap-
optosis) from values obtained for drug-treated cells. Equal percentage of specific DNA
fragmentation was detected after 48 hs of incubation with 0.12 µM taxol and 1.85 µM
epirubicin, respectively, in BJAB/mock and BJAB/FADDdn. As shown in Fig. 23, taxol-
as well as epirubicin-induced apoptosis was not significantly influenced by overexpres-
sion of FADDdn. Thus, drug-induced apoptosis in BJAB cells seems to be independent
of CD95/Fas signalling.
1 2 3
procaspase-8
processed 
caspase-8    pro
Fig. 22: Influence of Ac-DEVD-pNA on caspase-8 processing in vitro. Following 2 hs of activation,
samples were examined using Western blot analysis. (1) Ac-DEVD-pNA was added prior to addition of
cytochrome c and dATP, (2) Ac-DEVD-pNA was added after addition of cytochrome c and dATP; (3) no
colorimetric peptide substrate was added.61
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VII-4.2 MITOCHONDRIAL DEPOLARISATION
In recent publications, the critical role of mitochondrial damage for drug-induced apop-
tosis (Fulda et al., 1998, Melendez-Zajgla et al., 1999) and CD95-dependent signalling
to mitochondria via caspase-8-mediated cleavage of BID has been demonstrated (Li et
al., 1998). This BID cleavage product (tBID) is claimed to induce release of BAX from
the BAX/BCL-2 complex and thereby induce formation of large pores releasing cyto-
chrome c from the intermembrane space. Additionally, BID itself is reported to induce
this effect without cleavage to tBID by caspase-8 (Eskes, 1999). We thus measured mi-
tochondrial activation after treatment with taxol and epirubicin in our experimental sys-
tem. Treatment of BJAB/mock cells with both agents led to a significant mitochondrial
permeability shift and to a significant increase of cells with low ∆Ψm in a time dependent
manner. This drug-induced mitochondrial permeability transition was not influenced by
overexpression of FADDdn (Fig. 24), thereby excluding the possibility that the mito-
chondrial activation in BJAB cells was mediated by a CD95/Fas-dependent mecha-
nism. Time course experiments in BJAB/mock, BJAB/FADDdn cells revealed that the
mitochondrial permeability transition already occurred 24 hs after addition of epirubicin
and taxol to the culture medium and thus preceded or at least coincided with the pro-
cessing of procaspase-8. 
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Fig. 23: Drug-induced apoptosis in BJAB/FADDdn and BJAB/mock cells. Cells were incubated
with the indicated concentrations of cytostatic drugs for 48 hs and modified cell cycle analysis was per-
formed as described. Values are given as specific apoptosis ± S.D. (n = 3).62
Results VIIVII-4.3 CASPASE-3 AND CASPASE-8 WESTERN BLOT ANALYSIS
To further confirm that caspase-8 processing upon drug treatment in BJAB cells is in-
dependent of CD95/Fas signalling, Western blot analysis was performed. After chal-
lenge with taxol and epirubicin caspase-3 Western blot analysis was performed (Fig.
25, Fig. 26) and caspase-8 p18 was detected. The cleavage of caspase-8 in these cells
coincided with the appearance of the 17 kDa active subunit of caspase-3 and was not
delayed in comparison to drug-treated BJAB/mock cells. 
Fig. 24: Drug-induced loss of ∆Ψm in BJAB/mock versus BJAB/FADDdn cells.  BJAB/mock and
BJAB/FADDdn cells were incubated with the indicated concentrations of cytostatic drugs for different pe-
riods of time. Then mitochondrial membrane potential was analyzed by the JC-1 assay. Cells displaying
decreased mitochondrial membrane potential were scored as apoptotic. Results are given in percent of
10 000 events counted in FACS analysis.63
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VII-5 CYTOSTATIC DRUG TREATMENT OF NALM6 AND REH CELLS
As the results described above strongly indicated that processing and activation of
caspase-8 occurs separate from CD95/Fas signalling in BJAB/mock and BJAB/FAD-
Ddn cells, the question arose whether this is a general feature of CD95/Fas resistent
cells. To answer this question, two other B-lymphoid cell types, namely NALM6 and
REH, were used and DNA fragmentation and depolarisation of mitochondria was inves-
tigated using the appropriate assay systems. Furthermore, Western blot analysis was
performed to visualize caspase-8 processing.
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Fig. 25: Caspase-3 activation in BJAB/mock and BJAB/FADDdn cells. Cells were incubated with
or without cytostatic drugs for different periods of time as depicted. Caspase-3 activation was detected
using Western blot analysis. Positions of procaspase-3 and the 17 kDa subunit (p17) of the active het-
erotetramer are indicated at the right margin.
BJAB/mock BJAB/FADDdn
control
0.12 µM
taxol
1.85 µM
epirubicin control
0.12 µM
taxol
1.85 µM
epirubicin
procaspase-8
p18
caspase-8
Fig. 26: Caspase-8 activation in BJAB/mock and BJAB/FADDdn cells. BJAB/mock or dominant
negative FADD (FADDdn)-transfected BJAB cells were either left untreated or incubated with 0.12 µM
taxol or 1.85 µM epirubicin for 48 hs. Then, Western blot analyses were performed with anti-human
caspase-8 antibody. The positions of procaspase-8 and the 18 kDa active subunit of caspase-8 are in-
dicated at the right margin.64
Results VIIVII-5.1 DNA FRAGMENTATION IN NALM6 AND REH CELLS
To verify drug induced apoptosis in these two B-lymphoid cell types, modified cell cycle
analysis was performed. Cells were incubated with 0.12 µM taxol or 1.85 µM epirubicin
for up to 72 hs and the percentage of apoptotic cells was determined by flow cytometric
analysis. Results are shown in Fig. 27.
VII-5.2 MITOCHONDRIAL DEPOLARISATION IN NALM6 AND REH CELLS
NALM6 and REH cells were challenged with taxol or epirubicin for 24 hs and 48 hs and
depolarisation of mitochondria was detected by staining cells with the JC-1 dye and
subsequent flow cytometric analysis (Fig. 28). Loss of ∆ΨM  was already detected after
24 hs of treatment with taxol and epirubicin and reached up to 80 % - 90 % in REH cells.
NALM6 cells displayed about 40 % of drug-induced depolarisation of mitochondria after
48 hs of treatment with the respective cytostatic drugs.
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Fig. 27: DNA fragmentation in NALM6 and REH cells. Cells were treated with 0.12 µM taxol or 1.85
µM epirubicin for the indicated periods of time and subsequently modified cell cycle analysis was per-
formed as described. Number of hypodiploid cells is given as % specific apoptosis. 65
Results VII 
VII-5.3 ACTIVATION OF CASPASE-3 IN NALM6 AND REH CELLS
To render caspase-3 responsible for processing of caspase-8 in NALM6 and/or REH
cells first caspase-3 processing was assessed by caspase activity assay using the col-
orimetric peptide substrate Ac-DEVD-pNA. Cells were cultured in the presence or ab-
sence of taxol for 48 hs or epirubicin for 24 hs.
Fig. 28: Drug-induced loss ∆Ψm in NALM6 and REH cells.  Nalm6 and REH cells were incubated
with the indicated concentrations of cytostatic drugs for 24 hs and 48 hs. Then mitochondrial membrane
potential was analyzed by the JC-1 assay. Cells displaying decreased mitochondrial membrane poten-
tial were scored as apoptotic. Results are given in percent of 10 000 events counted in FACS analysis.
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Fig. 29: Induction of caspase-3 activity after drug treatment. NALM6 and REH cells were incubat-
ed with 0.12 µM taxol for 24 hs and 1.85 µM epirubicin for 48 hs. Cell extracts were prepared as de-
scribed and Ac-DEVD-pNA cleavage was determined by measurement of E405 in an ELISA reader. In
vitro activation of identical extracts was performed. Caspase-3-like activity of in vitro activated extracts
was defined as 100 %.66
Results VIIVII-5.4 CASPASE-8 ACTIVITY IN NALM6 AND REH CELLS
Ac-IETD-pNA cleavage was likewise examined. However, determination of the total
activity (i.e. 100 % caspase-8 activation after addition of cytochrome c and dATP) was
not possible. Thus, specific caspase-8-like activity was calculated on the basis of pro-
tein concentration and the absorption coefficient of the cleaved substrate. As shown in
Fig. 30, only in REH cells significant amounts of caspase-8-like activity were measured
after challenge with taxol and epirubicin, whereas in NALM6 cells induction of caspase-
8-like activity was not observed..
VII-5.5 PROCESSING OF CASPASE-8 IN NALM6 AND REH CELLS
In these experiments, effects of cytostatic drug treatment on caspase-8 processing
were examined in different B-lymphoid cell types by Western blot analysis. The mature
subunit p18 of caspase-8 was detected after 24 hs of treatment with the cytostatic
drugs (Fig. 31). These data confirmed caspase-8 processing in REH cells after induc-
tion of apoptosis by taxol and epirubicin. In accordance with the caspase-8 activity as-
say processing of caspase-8 was less pronounced in epirubicin-treated NALM6 cells.
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Fig. 30: Induction of caspase-8-like cleavage activity after drug treatment. NALM6 and REH cells
were incubated with 0.12 µM taxol for 48 hs and 1.85 µM epirubicin for 24 hs. Cell extracts were pre-
pared as described and Ac-IETD-pNA cleavage was determined by measurement of absorption in-
crease. Protein concentration was measured using the BCA assay kit and specific caspase-8-like activ-
ity was calculated in U/mg protein.67
Results VIIVII-6 SUMMARY OF FUNCTIONAL INVESTIGATIONS
The following list summarizes the functional characterization of caspase signalling in
B-lymphoid cell types
1. Cytostatic drug treatment of human B-lymphoid cells induces apoptosis 
(cleavage of PARP, processing and activation of caspase-3).
2. Caspase-9 is activated and mitochondrial membrane potential is disrup-
ted after challenge with cytostatic drugs.
3. Caspase-8 is also activated, but this activation is inhibited by the specific 
caspase-3 inhibitor Z-DEVD-fmk.
4. Caspase-3 depletion of cell free extracts blocks caspase-8 processing 
after addition of cytochrome c and dATP.
5. Time-dependent caspase-8 activation in cell free extracts shows a slo-
wer kinetic as compared with caspase-3 activation.
6. Caspase-8 activation is similar in BJAB/mock and BJAB/FADDdn trans-
fected cells.
procaspase-8
p18
BJAB/mock NALM6 REH
p18
procaspase-8
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Fig. 31: Drug-induced caspase-8 processing in BJAB/mock, NALM6 and REH cells. Ce l l s  were
incubated with 0.12 µM taxol (t), 1.85 µM epirubicin (e) or control medium (c) for 24 hs (A) and 48 hs (B).
Caspase-8 processing was detected using Western blot analysis. The positions of procaspase-8 and
the mature 18 kDa subunit (p18) are indicated at the right margin.68
Results VIIVII-7 DETECTION OF APOPTOSIS RELATED PROTEINS
High resolution 2DE-PAGE is the state of the art method to identify yet unknown (apo-
ptosis related) proteins. Therefore, this method was used to examine effects of cyto-
static drugs in the experimental system, i.e. in BJAB cells. To obtain further information
about apoptosis related proteins, BJAB cells transfected with crmA were used. CrmA
(cytokine response modifier A) is an antiapoptotic protein derived from the cow pox vi-
rus mainly inhibiting caspase-8 (Ki = 0.3 - 0.95 nM)but also caspase-3 (Ki = 1600 nM)
(Zhou et al., 1997). BJAB/crmA cells should show the same regulatory response to cy-
tostatic drug treatment as compared to mock-transfected controls. On the other hand,
the response downstream of caspase activation should be inhibited. In first experi-
ments, standard markers of apoptosis were examined, e.g. DNA fragmentation, depo-
larisation of mitochondria, PARP-cleavage and activation of caspases. These
experiments are shown in detail below. Taken together, apoptosis was significantly de-
layed in BJAB/crmA cells in comparison with vector control transfected BJAB/mock
cells but not abolished.
VII-7.1 DNA FRAGMENTATION IS DELAYED IN CRMA TRANSFECTED BJAB CELLS
To assess downstream events in apoptotic cell death DNA fragmentation upon treat-
ment with cytostatic drugs was examined. BJAB/crmA cells were incubated with 0.12
µM taxol and 1.85 µM epirubicin for 24 hs, 48 hs and 72 hs and hypodiploid cells were
quantified by flow cytometric analysis (Fig. 32). This experiment revealed that DNA
fragmentation is clearly delayed in crmA transfected cells. However, apoptosis was not
completely blocked. Apoptosis in these cells reached about 20% after 72 hs of drug-
treatment. 
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Fig. 32: DNA fragmentation is reduced in crmA-transfected BJAB cells. BJAB/mock and BJAB/
crmA cells were incubated with cytostatic drugs for different periods of time as indicated. Modified cell
cycle analysis (10000 events counted) showed that crmA transfection had significant impact on
percentage of hypodiploid cells.69
Results VIIVII-7.2 CASPASE-3 ACTIVATION IS DELAYED IN CRMA TRANSFECTED BJAB CELLS
Caspase-3 Processing
Caspase-3 processing after treatment of BJAB/crmA cells was examined by Western
blot analysis. The intensity of the immunoreactive band representing the mature sub-
unit of caspase-3, p17, was significantly reduced after 24 hs and 48 hs of cytostatic
drug treatment in BJAB/crmA cells as compared to BJAB/mock cells but increased until
72 hs of treatment (Fig. 33). This indicated that caspase activation is strongly inhibited
but not blocked in crmA-transfected BJAB cells.
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Fig. 33: Caspase-3 processing is delayed in BJAB/crmA. A) BJAB/crmA cells were incubated with
cytostatic drugs for different periods of time as indicated and Western blot analysis was performed as
described. The positions of procaspase-3 and the active 17 kDa subunit, p17, are indicated at the right
margin. B) As a control, BJAB/mock cells were likewise incubated with cytostatic drugs and caspase-3
processing was analyzed.70
Results VIIVII-7.3 HIGH RESOLUTION 2DE-PAGE
After characterization of the crmA-transfected cell line samples were prepared for 2DE
PAGE. Analytical two dimensional gel electrophoresis was performed. The gels were
stained according to the protocol of Heuckeshofen et al. (1985). Subtractive analysis
revealed several spots varying in intensity, especially in the low molecular weight
range. Further information was deduced from comparison of samples derived from the
two different cell lines (BJAB/mock and BJAB/crmA) as well as treatment with the re-
spective cytostatic drugs. On basis of this overall correlation, it is a plausible consider-
ation that most of the spots displaying decreased intensity in samples of drug-treated
cells represented caspase substrates. Thus, taxol and epirubicin resulted in decrease
of the same spots which therefore are assumed to be related to apoptosis in general
and not to regulatory effects of these cytostatic drugs which head for different cellular
agents. Moreover, the experiments showed that spot variations were the same in
BJAB/mock and BJAB/crmA cells although drug-induced effects were in BJAB/crmA
cells were delayed in general. Further experiments were therefore performed exclu-
sively with BJAB/mock.
Altered spots were cut from preparative gels, digested with trypsin and mass spectro-
metric analysis was performed. Moreover, not only spots displaying changes in inten-
sity but also spots representing proteins with obviously constant protein concentration
were identified in order to calibrate the 2DE gels with respect to the apparent molecular
weight and pH gradient. Results of data bank searches are given in table 8 and posi-
tions of corresponding spots on 2DE PAGE gels are shown in Fig. 34. Enlargements
of certain areas are shown in Fig. 35 - Fig. 39. Mass spectrometric analysis was per-
formed by Eva-Christina Müller.71
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Fig. 34:  Representative 2DE PAGE gel. Two dimensional separation of proteins from a control sam-
ple is shown. Spots within the indicated areas A - E were identified by mass spectrometric analysis. Re-
sults were correlated with those obtained from cytostatic drug-treated cells and cell extracts with or with-
out in vitro activation as depicted on the following pages. Colors indicate change in spot intensity: white:
no significant change; grey: decrease; black: increase. The identity of the spots is given in table 8.72
Results VII    
Table 8: Spots identified by mass spectrometric analysis.  The corresponding positions 
are indicated in Fig. 34. 
Spot Number Protein (SwissProt)
Accesion 
Number
comments
1 P00248 Ubiquitin
2 THIO P10599 Thioredoxin
3 TBB1 P07437 Tubulin β-1 chain
4 Q15336 Li-Cadherin
5 YHIT P49774 Hypothetical HIT-likeprotein U296A
6 ACTB P02570 β-Actin, increase, C-terminal fragment
7 AR16 O15511 ARP2/3 complex 16 KDA subunit
8 FABE Q01469 Fatty acid binding protein
9 G3P2 P04406 Glyceraldehyd 3-phosphate dehydrogenase
10 RLA2 /
MLEN
P05387 /
P16475
60S acidic ribosomal protein P2/
Myosin light chain alkali, non-muscle isoform
11 ACTB P02570 β-Actin, increase, N-terminal fragment
12 NUCL P19338 Nucleolin, increase, fragment
13 CYPH P05092 Cyclophilin A, increase
14 STHM P16949 Stathmin
15 DEST P18282 Destrin / actin depolymerizing factor
16 BTF3 P20290 RNA polymerase B transcription factor 3, 
decrease
17 DUT P33316 Deoxiuridine 5’-triphosphate nucleotidohydro-
lase, decrease
18 TDX1 P32119 Thioredoxin peroxidase 1
19 G3641298 FIFO type ATPase
20 TDX2 Q06830 Thioredoxin peroxidase 2
21 GDIS P52566 Rho GDP-dissociation inhibitor 2, increase
22 TDX2 Q06830 Thioredoxin peroxidase 2
23 GTP P09211 Glutathione S-transferase P
24 GTP P09211 Glutathione S-transferase P
25 GDIS P52566 Rho GDP-dissociation inhibitor 2, decrease
26 RANG P43487 RAN-specific GTPase-activating protein
27 GDIR P52565 Rho GDP-dissociation inhibitor 173
Results VII28 TCPD P50991 T-complex protein 1, δ subunit, increase
29 PRC8 P25788 Proteasome component C8
30 IF4H Q15056 eukaryotic translation initiation factor 4H
31 PNPH P00491 Purine nucleoside phosphorylase
32 ICE3 P42574 Caspase-3 (proform), decrease
33 ANX4 P09525 Annexin IV
34 HSU86782 Pad1
35 ENOA P06733 Alpha Enolase
36 ROA2 P22626 Heterogeneous nuclear ribonucleoprotein A2/B1
37 EST: 
G1303338
38 PIR:JW0079 hnRNP like protein
39 G3P2 P04406
40 IDHA P50213 Socitrate dehydrogenase (NAD) subunit α, mito-
chondrial
41 CABA Q99020 CARG-binding factor-A (mouse)
42 LA P05455 Lupus LA protein
Table 8: Spots identified by mass spectrometric analysis.  The corresponding positions 
are indicated in Fig. 34. 
Spot Number Protein (SwissProt)
Accesion 
Number
comments
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Fig. 35: (AREA A) Decrease of procaspase-3. Cells or cellular extracts were treated as indicated in
the figure. Then, 2DE PAGE analysis was performed. 32 = procaspase-3; 35 = alpha enolase; 31 = pu-
rine nucleotide phosphorylase.74
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Fig. 36: (AREA B) Detection of a nucleolin and β-actin fragment. 2DE PAGE analysis was per-
formed after cytostatic drug-treatment or after in vitro activation as indicated in the figure. 17 = DUT; 14
= STHM; 12 = nucleolin (fragment); 11 = β-actin (fragment); 8 = FABE; 4 = poly-c.75
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Fig. 37: (AREA C) Decrease of D4-GDI concentration. After treatment of cultured cells or cellular ex-
tracts as indicated in the figure, 2DE PAGE analysis was performed. 29 = PRCδ; 27 = rho-GDI; 25 = D4-
GDI; 26 = RANG; 23 and 24 = GTP; 19 = FIFO type ATPase; 18 = TDX1.
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Fig. 38: (AREA D) D4-GDI-fragment and tcpd-fragment. Increase in intensity of the spots identified
as D4-GDI (fragment, spot #21) and t-complex binding protein (δ-subunit, fragment, spot #28) was
readily detected in lysates of drug-treated BJAB/mock cells and cell extracts after induction of the mito-
chondrial apoptotic cascade after performing 2DE PAGE.76
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Fig. 39: (AREA E) BTF3 and β-actin fragment. Protein samples of drug-treated cells or in vitro acti-
vated extract and control samples were separated by 2DE PAGE. Results are shown above. Change in
intensity of the spots representing the transcription factor BTF3 (spot #16) and an β-actin fragment (spot
#6) was, as shown above, significant. 16 = BTF3; 15 = destin; 13 = cyclophilin A; 9 = G3P2; 6 = β-actin
(fragment); 5 = hint protein.77
Results VIIAreas containing spots displaying significant variability in intensity are enlarged in Fig.
35 - Fig. 39. Significant decrease of intensity was detected for procaspase-3, D4-GDI,
DUT whereas spot intensity was obviously increased for fragments of β-actin, nucleo-
lin, D4-GDI, tcpd and a spot representing cyclophilin A. One of the most variable spots
was identified as D4-GDI. In the following investigations, the significance and mecha-
nism of this phenomenon was studied in detail.
VII-8 D4-GDI IN DRUG INDUCED APOPTOSIS
D4-GDI (rho-GDI 2) is one of three known small GTP dissociation inhibitors and exclu-
sively expressed in haematopoietic tissues. Rho-GDI (rho-GDI 1) is expressed ubiqui-
tously and rho-GDI 3 in brain, lung kidney, testis and pancreas (Sasaki and Takai,
1998). Since the intensity of the identified spot representing D4-GDI significantly de-
creased upon treatment of BJAB cells with cytostatic drugs further investigation intend-
ed to clarify several questions, e.g. if D4-GDI is specifically cleaved during apoptosis
and if so, which caspase or protease is responsible for cleavage of D4-GDI (Brockstedt
et al., 1998).
VII-8.1 D4-GDI / RHO-GDI IS SPECIFICALLY CLEAVED DURING APOPTOSIS
BJAB/mock cells and BJAB/crmA cells were cultured in the presence or absence of
0.12 µM taxol or 1.85 µM epirubicin for 24 hs, 48 hs and 72 hs. After determination of
protein concentration, 15 µg of protein were separated by SDS-PAGE and blotted onto
NC membrane followed by Western blot analysis using a pAb specific for rho-GDI and
D4-GDI (Fig. 40).
In response to cytostatic drug treatment one additional band was detected. As the de-
crease of D4-GDI concentration during apoptosis had already been shown by 2DE
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Fig. 40: Cleavage of rho-GDI / D4-GDI after drug treatment of BJAB cells. BJAB/mock and BJAB/
crmA cells were incubated with cytostatic drugs for the indicated periods of time. Western blot analysis
revealed the specific cleavage of either rho-GDI or D4-GDI. The positions of the bands representing rho-
/D4-GDI and the corresponding fragment are indicated at the right margin.78
Results VIIPAGE it was reasonable that this band represented a D4-GDI fragment resulting from
specific cleavage of the full length protein during apoptosis. Nonetheless, there was yet
no information about the effects of drug treatment on rho-GDI in BJAB cells and addi-
tional experiments were necessary to obtain further information about the origin of the
appearing band.  
VII-8.2 2DE PAGE AND WESTERN BLOT ANALYSIS
To determine the identity of the immunoreactive bands proteins were separated by an-
alytical 2DE PAGE and blotted onto NC membranes. Proteins were visualized by Pon-
ceau Red staining and subsequently membranes were scanned on a Linotype Hell flat
bed scanner. Western blot analysis was performed using the above mentioned pAb
specific for rho-GDI and D4-GDI, and immunoreactive spots were visualized using the
ECL detection system (Fig. 42). Three protein spots were detected which were as-
sumed to represent rho-GDI 1, D4-GDI (rho-GDI 2) and a fragment of one of these pro-
teins. The position of detected spots was correlated with Ponceau staining of the
membranes using computer aided image processing. As the spot representing D4-GDI
had already been identified (spot #2, Fig. 42) the immunoreactive spot located at a
higher apparent molecular weight and lower isoelectric point (spot #1, Fig. 42) was con-
sidered to be rho-GDI and the third spot, located at lower apparent molecular weight
(about 23 kDa) and higher isoelectric point, was considered to represent the fragment
formed upon induction of apoptosis (spot #3, Fig. 42). 79
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Fig. 41: Example of a 2DE PAGE gel. The indicated region of the 2DE PAGE gel and results obtained
by Western blot analysis of the corresponding area are correlated in detail in Fig. 42. 80
Results VIIVII-8.3 IDENTIFICATION OF THE IMMUNOREACTIVE SPOTS
As the identity of the spots still had to be confirmed again 2DE PAGE was performed
(analytical scale) and proteins were visualized by staining according to Blum et al. fol-
lowed by spot excision, tryptic digest and mass spectrometric examination of the result-
ing peptide mixtures. Data bank search on the basis of peptide masses and internal
sequences led to confirmation of the results obtained by Western blot analysis of the
2DE gels (Fig. 42). This indicates that D4-GDI is specifically cleaved by one of the
caspases activated during drug-induced apoptosis. Cleavage of rho-GDI 1 does not oc-
cur as the concentration of rho-GDI 1 did not change in samples derived from apoptotic
cells. Sequence analysis of rho-GDI and D4-GDI revealed that rho-GDI lacks a specific
caspase-3 cleavage site which is only present in D4-GDI. Thus, it was likely that the
fragment represents a cleavage product of D4-GDI resulting from caspase-3 activity.
Mimicing mitochondrial activation of the apoptotic cascade which primarily activates
caspase-9 and caspase-3, was performed to obtain further information about the se-
quential caspase cascade responsible for D4-GDI cleavage.
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Fig. 42: Correlation of Western blot analysis and silver stain of 2DE PAGE gels. 2DE PAGE gels
of drug-treated (0.12 µM taxol, 72 hs) BJAB/mock cells were prepared in parallel and either silver
stained (A and B) or blotted and analyzed using a rho-GDI / D4-GDI specific antibody. The positions of
the immunoreactive spots are indicated in A and B, the overall location of the area taken for Western blot
analysis is depicted in Fig. 41. Spot 2 was already identified as D4-GDI, spot #1 was assumed to repre-
sent rho-GDI and spot #3 represents a fragment of either of this proteins.81
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INDUCES D4-GDI CLEAVAGE.
In order to obtain larger amounts of the cleavage product it was tested whether rho-GDI
1 / D4-GDI was cleaved after in vitro activation of cellular extracts derived from  BJAB/
mock cells. Mitochondrial initiation of the caspase cascade was achieved by addition
of 10 µM cytochrome c and 1 mM dATP followed by incubation at 30°C for 5 min. The
control sample was kept on ice without addition of cytochrome c and dATP. After acti-
vation, a time course was obtained by taking samples of equal volume from both ex-
tracts after different periods of time and proteins were immediately denatured by
addition of excess sample buffer (5xPP) and boiling at 95°C for 5 min. Subsequent
Western blot analysis revealed that rho-GDI 1 / D4-GDI was specifically cleaved only
in activated extracts thereby confirming that a caspase which had been activated
downstream of the mitochondrial initiation of the caspase cascade was necessary to
cleave rho-GDI 1 / D4-GDI producing the observed fragment (Fig. 43).
  
Thus, induction of the mitochondrial caspase cascade lead to formation of the band
representing the D4-GDI fragment and allowed production of larger amounts of the
fragment by in vitro activation of extracts. The resulting protein mixture was then used
for further analysis by 2DE PAGE. Specific cleavage of D4-GDI (decrease in spot in-
tensity) and formation of the spot in question (increase in intensity) was also confirmed
detected in analytical 2DE gels (Fig. 44). 
procaspase-3
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Fig. 43: Formation of the rho-GDI 1 / D4-GDI fragment after in vitro activation. Cell extracts were
prepared and the mitochondrial caspase cascade was initiated by addition of cytochrome c and dATP.
Samples were analyzed by Western blot analysis using anti-caspase-3 Ab (A) or anti-rho-GDI 1 / D4-
GDI Ab (B). The positions of the respective protein bands are indicated at the right margin.82
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Fig. 44: Rho-GDI 1, D4-GDI and D4-GDI fragment in 2DE PAGE gels of cell free extracts.  Ex -
tracts were prepared as described and protein samples were separated using semipreparatve 2DE
PAGE followed by silverstaining according to Blum et al. (1987). Positions of the identified spots are in-
dicated and enlarged areas correspond to those depicted in Fig. 41. 1 = rho-GDI 1; 2 = D4-GDI; 3 frag-83
Results VIIVII-8.5 ROLE OF CASPASE-1 IN DRUG-INDUCED APOPTOSIS
D4-GDI has been reported to be a substrate for caspase-3 (Na et al., 1996) and
caspase-1 (Danley et al., 1996). In previous experiments, caspase-3 activation of
caspase-3 has already been shown. However, effects of cytostatic drug treatment on
caspase-1 processing and activation still had to be examined. This was necessary be-
cause experimental evidence had been provided that caspase-1 is activated during ap-
optosis, at least after taxol treatment (Ibrado et al., 1998, Kottke et al., 1999).
Western Blot Analysis
Protein samples derived from BJAB/mock cells incubated with 0.12 µM taxol or 1.85
µM epribucin were used for SDS-PAGE,  blotted onto NC membrane and a pAb was
used to detect procaspase-1 (see Fig. 45 A). A time-dependent decrease in pro-
caspase-1 content was observed. On the other hand, using an Ab specific for the ma-
ture caspase-1 p20 subunit, an increase of p20 was not detected (Fig. 45 B) indicating
that caspase-1 is degraded rather than processed to form the active enzyme. 
Nonetheless, the data obtained so far did not exclude a role of caspase-1 in drug in-
duced apoptosis, and the possibility of caspase-1 activation was further investigated
using the caspase-1 specific colorimetric substrate Ac-WEHD-pNA. 
Caspase-1 Activity Assay
BJAB/mock cells were either treated with control medium, incubated with 0.12 µM taxol
or 1.85 µM epirubicin for 48 hs and cell extracts were prepared. Extracts were either
activated by addition of cytochrome c and dATP and incubation at 30°C for 30 min or
control 0.12 µM taxol 1.85 µM epirubicin
24 hs 48 hs 72 hs 24 hs 48 hs 72 hs24 hs 48 hs 72 hs
p20
subunit
Procaspase-1
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Fig. 45: Cleavage of procaspase-1 in drug-treated BJAB cells. Western blot analysis of identical
samples used for detection of caspase-3 processing and PARP cleavage. A time-dependent decrease
in procaspase-1 content is clearly visible (A). However, using a caspase-1 p20 specific Ab, an increase
in p20 content was not detected (B).84
Results VIIkept on ice without addition of supplements. For detection of caspase-1-like activity Ac-
WEHD-pNA was used. This substrate reflects the preferred caspase-1 substrate se-
quence (Rano et al., 1997) and cleavage after Asp1 releases pNA resulting in an in-
crease of absorption at 405 nm. Absorption was measured after 3 hs of incubation at
37°C and no significant increase in absorption was detected when samples from cyto-
static drug-treated cells were compared with control extracts. Since this experiment
was performed in parallel with a caspase-3 activity assay (Fig. 46) it was clearly exclud-
ed that activation of caspase-1 plays a role during drug-induced apoptosis in BJAB
cells.
VII-8.6 IS D4-GDI CLEAVED IN VIVO AND IN VITRO  BY CASPASE-3 OR CASPASE-1?
This question was answered using different methods. On the one hand, in vivo exper-
iments using irreversible peptide inhibitors specific for caspase-1 and caspase-3 were
performed. Second, the colorimetric substrate Ac-DEVD-pNA was used as a competi-
tive inhibitor in vitro, and third, caspase-3 was depleted from cellular extracts prior to
activation. Finally, the obtained results were confirmed using mass spectrometric
methods to analyze the cleavage site in vivo.
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Fig. 46: Caspase-3-like and caspase-1-like activity assay after drug treatment. BJAB/mock cells
were left untreated or incubated with 0.12 µM taxol or 1.85 µM epirubicin for 48 hs. Cell extracts were
prepared and Ac-DEVD-pNA or Ac-WEHD-pNA were used for detection of caspase activities.85
Results VIITaxol-induced D4-GDI Cleavage is Blocked by Z-DEVD-fmk but not by Z-WEHD-fmk 
in Cultured BJAB/mock Cells
BJAB/mock cells were induced to undergo apoptosis by addition of 0.12 µM taxol in the
presence or absence of Z-DEVD-fmk and Z-WEHD-fmk which specifically inhibit
caspase-3 and caspase-1 activity, respectively. Cells were harvested after 48 hs of in-
cubation. Subsequently, Western blot analysis was performed using the D4-/rhoGDI
specific Ab. D4-GDI cleavage was nearly blocked in samples cultured in the presence
of caspase-3 inhibitor whereas caspase-1 inhibitor had no significant effect (Fig. 47). 
Ac-DEVD-pNA Blocks D4-GDI Cleavage In Vitro
The specific caspase-3 colorimetric substrate Z-DEVD-pNA was used as competitive
inhibitor in activated cell extracts of BJAB/mock control cultures. Sample preparation
and in vitro activation of caspases were done as described. Western blot analysis using
anti-rho-GDI 1 / D4-GDI Ab was performed and showed clear inhibition of D4-GDI
cleavage by Ac-DEVD-pNA (Fig. 48). Thus, it is concluded that D4-GDI is a substrate
of caspase-3, at least in vitro.
0.12 µM taxol 
 + DEVD
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Fig. 47: Z-DEVD-fmk but not Z-WEHD-fmk blocks D4-GDI cleavage. BJAB/mock cells were incu-
bated with 0.12 µM taxol in the presence or absence of Z-DEVD-fmk or Z-WEHD-fmk for 48 hs. Western
blot analysis was performed using anti-rho-GDI 1 / D4-GDI Ab as described in Methods. The positions
of D4-GDI / rho-GDI and D4-GDI fragment are indicated at the right margin.
Rho-/D4-GDI
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Fig. 48: Ac-DEVD-pNA inhibits cleavage of D4-GDI in vitro. Cellular extracts from BJAB/mock cells
were prepared and in vitro activated before, after or without addition of Ac-DEVD-pNA. Samples ob-
tained after the indicated periods of time were analyzed by Western blot analysis using anti-rho-GDI 1 /
D4-GDI Ab. The positions of rho-/D4-GDI and the corresponding fragment are indicated at the right mar-
gin.86
Results VIIImmunoprecipitation of Caspase-3 in Vitro
This experiment was performed exactly as described under VII-3.3. Samples were
analysed using anti rho-GDI 1 / D4-GDI Ab. Results are shown in Fig. 49 and confirm
the necessity of active caspase-3 for D4-GDI cleavage, as already indicated by the in-
hibitor experiments.
VII-8.7 EXACT DETERMINATION OF THE D4-GDI CLEAVAGE SITE IN VIVO
N-terminal Edman sequencing needs far more protein as compared with mass spec-
trometric methods. Furthermore, it is very difficult to obtain large amounts of protein
from apoptotic cells. Therefore, mass spectrometry was chosen to identify the exact in
vivo cleavage site of D4-GDI. Detailed analysis of peptide mass fingerprints from full
length D4-GDI and the corresponding fragment was performed. Subsequent microse-
quencing of peptides by MS/MS revealed the presence of the peptide
E34LQEMDKDDESLIK47 (see Fig. 50) in both samples. Since the cleavage site of
caspase-3 is represented by DELD19S and the cleavage site of caspase-1 by
LLGD55G the detection of this peptide, located between Lys33 and Tyr48  of D4-GDI, in
the samples derived from D4-GDI fragment was only consistent with the caspase-3-
mediated cleavage of D4-GDI after drug-induced apoptosis (see also Fig. 50).
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Fig. 49: Immunochemical depletion of procaspase-3 inhibits D4-GDI cleavage. Cell extracts were
prepared as described and incubated with protein-A sepharose with (+Ab) or without (-Ab) procaspase-
3 specific Ab prior to activation. Protein-A sepharose was sedimented by centrifugation. The clear su-
pernatant was used for in vitro activation. Samples were removed after different periods of incubation at
30°C (as indicated) and analyzed by Western blot using a rho-GDI 1/D4-GDI specific Ab.87
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VII-9 APPROACHES TO IDENTIFY APOPTOSIS REGULATING PROTEINS
So far the role of caspases in drug-induced apoptosis, especially caspase-9, caspase-
8, caspase-3 and caspase-1, had been well elucidated. Furthermore, D4-GDI was
identified to be specifically cleaved by caspase-3 during this process while rho-GDI
was not affected. On the basis of these results, additional attempts were made to iden-
tify yet unknown caspase substrates or proteins involved in regulation of drug-induced
apoptosis in BJAB cells. Although it is possible to separate more than 10000 proteins
in high resolution 2DE PAGE this method alone was obviously not suitable to obtain
the desired results when entire cell lysates were used for analysis. This is reflected by
the low copy numbers of regulatory proteins and detection of proteins by silverstain is
limited to 1 ng - 10 ng of protein per spot. Thus, additional approaches had to be per-
formed in order to study regulatory effects of cytostatic drug treatment on yet unknown
proteins: (I) cell fractionation prior to 2DE PAGE on the basis of characteristics different
from apparent molecular weight and isoelectric point was used and (II) the detection
limit of protein analysis was lowered by metabolic radioactive labeling of proteins.
VII-9.1 CELL FRACTIONATION USING MAGNETIC ANNEXIN V-BEADS
In living cells, membrane assymmetry is maintained by the flipase which keeps phos-
phatidylserine (PS) on the inner side of the membrane by an ATP-dependent process.
On the other hand, apoptosis is an active ATP-consuming process and breakdown of
mitochondrial membrane potential abolishes ATP production. As a consequence, ATP
is no longer provided for energy consuming proteins, i.e. the flipase, and membrane
asymmetry breaks down resulting in exposure of PS to the outer membrane site. This
effect can be used to enrich apoptotic cells or to deplete them from samples. To enrich
D4-GDI: 
  1 MTEKAPEPHV EEDDDDELDS KLNYKPPPQK SLKELQEMDK
 41 DDESLIKYKK TLLGDGPVVT DPKAPNVVVT RLTLVCESAP
 81 GPITMDLTGD LEALKKETIV LKEGSEYRVK IHFKVNRDIV
121 SGLKYVQHTY RTGVKVDKAT FMVGSYGPRP EEYEFLTPVE 
161 EAPKGMLARG TYHNKSFFTD DDKQDHLSWE WNLSIKKEWT E
D4-GDI fragment:
  1 MTEKAPEPHV EEDDDDELDS KLNYKPPPQK SLKELQEMDK
 41 DDESLIKYKK TLLGDGPVVT DPKAPNVVVT RLTLVCESAP 
 81 GPITMDLTGD LEALKKETIV LKEGSEYRVK IHFKVNRDIV 
121 SGLKYVQHTY RTGVKVDKAT FMVGSYGPRP EEYEFLTPVE 
161 EAPKGMLARG TYHNKSFFTD DDKQDHLSWE WNLSIKKEWT E
caspase-3 cleavage site caspase-1 cleavage site
Fig. 50: D4-GDI sequence and identified peptides. Peptides identified by mass spectrometric analy-
sis are printed in bold. Identification of E34LQEMDKDDESLIK47 revealed that the D4-GDI fragment re-
sulted from cleavage by caspase-3 rather than caspase-1.88
Results VIIapoptotic cells, magnetic beads covalently coupled with Annexin V, a protein which
specifically binds to PS, were used. Samples of BJAB/mock cells treated with 0.12 µM
taxol or 1.85 µM epirubicin were incubated with Annexin V coupled magnetic beads
and separation was then performed in the presence of a magnetic field. Cells bound to
magnetic beads (apoptotic cells) were retained and unbound cells (non-apoptotic) cells
passed the column. Finally, apoptotic cells were eluted by removal of the magnetic
field. Cells which had been separated by this technique were analyzed by 2DE PAGE.
Then, the silverstained gels were submitted to subtractive analysis. However, spots
displaying differential intensity fitted those detected in whole cell lysates. However,
these data revealed that purification of apoptotic cells did not sufficiently enhance spec-
ificity and sensitivity of the analysis (results not shown). Thus, cell fractionation by the
use of Annexin-V coupled magnetic beads did not significantly improve the experimen-
tal approach.
VII-9.2 METABOLIC 35S-LABELLING
In these experiments, BJAB/mock cells were starved by incubation in methionine/cys-
teine free medium and apoptosis was induced using taxol or epirubicin. Radioactive
methionine and cysteine were added simultaneously to the apoptotic stimulus and the
cells were incubated for different periods of time (6 - 24 hs). This short incubation times
were chosen because regulatory effects should occur prior to activation of the apoptotic
cascade, which had been shown to occur after 24 hs. Cells were harvested and sam-
ples were prepared for 2DE PAGE. After separation of proteins, gels were either fixed,
dryed immediately and exposed to x-ray films or silverstained prior to exposure to x-
ray-films. This was done to compare protein patterns resulting from autoradiography
and normal protein staining.
At least one spot displaying significant difference in intensity after cytostatic drug-treat-
ment could be visualized by this technique (Fig. 51). Protein staining revealed low
abundance of the protein and despite several attempts the protein representing this
spot has not been identified yet.
1.85 µM epirubicincontrol
Fig. 51: Differentially expressed spot after epirubicin treatment. BJAB/mock cells were treated
with epirubicin or control medium for 8 hs and proteins were labeled with 35S-methionine/cysteine. 2DE
PAGE analysis was performed and the resulting autoradiographies were submitted to subtractive anal-
ysis. The position of one spot displaying a significant change in intensity is indicated. 89
Discussion VIIIVIII DISCUSSION
Three major starting points of apoptosis are under discussion in the literature: (I) death
receptors (DRs) (Schulze-Osthoff, 1998 and literature cited therein), (II) mitochondria
(ER) (Liu, 1996, Loeffler and Kroemer, 2000) and (III) the endoplasmic reticulum. Much
is known about DR-signalling as well as the death cascade induced by mitochondria
whereas only little is known about death induced by ER-stress (Nakagawa, 2000).
DR-signalling in general is mediated by oligomerisation of the receptor. This induces
binding of adaptor molecules on the inner membrane part of the receptor (formation of
the DISC) thereby mediating recruitment of procaspases and subsequent autopro-
teolytic activation. Within the CD95/Fas-signalling pathway caspase-8 is believed to be
the initiator caspase leading to downstream activation of the executioner caspases,
which are caspase-3, -6 and -7.
A similar mechanism is published for the mitochondrial induction of the caspase cas-
cade. BCL-2 family proteins are supposed to regulate loss of mitochondrial membrane
potential and release of apoptogenic factors, like cytochrome c. Then, cytochrome c,
APAF-1 and dATP build up the mitochondrial DISC, the initiator caspase, procaspase-
9, is incorporated and autoproteolytically activated. Active caspase-9 then mediates
activation of the effector caspases.
Only little is known about regulation of ER-stress induced apoptosis. However, pro-
caspase-12 is thought to be the initiator-caspase within this signalling pathway.
Although the first two signalling pathways are quite well documented there is an ongo-
ing debate about death induced by cytostatic drugs. On the one hand, some authors
announce induction of FasL expression upon cytostatic drug treatment and autocrine
or paracrine induction of apotosis mediated via CD95/Fas (Friesen et al., 1996, Friesen
et al., 1997, Müller et al., 1997, Fulda et al., 1997, Fulda et al., 1998). On the other
hand, FasL expression is not found by others upon cytostatic drug treatment and in-
duction of apoptosis is claimed to be independent of CD95/Fas (McGahon et al., 1998,
Adjei et al., 1998, Eischen et al., 1997, Micheau et al., 1999). Since most of the work
on drug-induced apoptosis has been done in T cells, namely Jurkat cells, the present
study aims to elucidate the signalling pathways involved in drug-induced apoptosis in
B-lymphoid cells upon treatment with taxol and epirubicin.
VIII-1 THE CASPASE CASCADE
VIII-1.1 THE MITOCHONDRIAL SIGNALLING PATHWAY
Cytostatic drug-induced apoptosis is reported in several publications to be mediated
via activation of mitochondria and subsequent release of cytochrome c either via outer
membrane rupture or opening of a channel large enough for cytochrome c to pass
through (Reed, 1997). This leads to formation of the mitochondrial DISC, consisting of90
Discussion VIIIAPAF-1, cytochrome c and dATP, inducing a conformational change in APAF-1 (Qin et
al., 1999) thereby recruiting procaspase-9 to the complex and leading to autoproteolyt-
ic activation of procaspase-9 (Zou et al., 1999). Once activated, caspase-9 processes
the predominant effector caspase-3. Besides caspase-3, caspase-6 and caspase-7
are also reported to be activated (Bratton et al., 2000). Further downstream events in
cells undergoing apoptosis are represented by the cleavage of the prototypic caspase-
3 substrate PARP resulting in the formation of a 84 kDa fragment and DNA fragmen-
tation mediated by CAD (caspase activated DNase) or AIF (apoptosis inducing factor).
In order to examine effects of taxol and epirubicin-treatment on BJAB/mock cells sev-
eral events associated with apoptosis were investigated. First, the outcome of drug
treatment was investigated: Cell death. BJAB/mock cells were shown to die after treat-
ment with taxol and epirubicin using the trypan exclusion assay which discriminates be-
tween dead and living cells. In order to provide evidence for apoptosis to occur rather
than necrosis downstream events of the apoptotic cascade were investigated. It was
shown by flow cytometric analysis that, in accordance with published data, both drugs
induce DNA fragmentation at a significant level (50 % - 60 %). The experimental setup
was further characterized by Western blot analysis and cleavage of PARP as well as
proteolysis of procaspase-3 was shown to specifically occur in drug-treated BJAB/
mock cells. These data confirmed that the chosen concentrations of taxol (0.12 µM)
and epirubicin (1.85 µM) clearly induce apoptosis.
While the aim of this study was of more general concern it was shown that the reported
upstream events of the mitochondrial apoptotic pathway are also characteristic for
drug-induced apoptosis in BJAB/mock cells. Western blot analysis revealed that pro-
caspase-9 is processed after drug treatment. This is reported to be mediated by forma-
tion of the mitochondrial DISC (Liu, 1996) after release of cytochrome c and
depolarization of mitochondria (Bossy-Wetzel et al., 1998). It was therefore tested
whether procaspase-9 is processed and depolarization of mitochondria can be detect-
ed in drug treated BJAB/mock cells. Western blot analysis confirmed caspase-9 pro-
teolysis and flow cytometric analysis using the JC-1 dye showed significant loss of
mitochondrial membrane potential specifically after drug-treatment of BJAB/mock cells
reaching up to 60 % - 80 % after 72 hs. Taken together these data provide strong evi-
dence for induction of the mitochondrial apoptotic pathway in BJAB cells upon treat-
ment with taxol and epirubicin at the given concentrations.91
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However, the involvement of the CD95/Fas signalling pathway in cytostatic drug-in-
duced apoptosis had to be investigated as the role of CD95/Fas signalling in drug-in-
duced apoptosis is discussed controversely. This is true for T-cell and B-cell apoptosis
and it is a matter of debate if death receptor signalling is functionally or even involved
at all in drug-induced apoptosis. One reason for controversy might be the origin of the
published data with regard to the different cell types and apoptotic stimuli used. An at-
tempt to include the contradictory results in one theory leads to the current model for
induction of apoptosis which divides cells in two classes (Scaffidi et al., 1998):
• type I cells, in which apoptosis is mediated via Fas-ligation and subsequent activa-
tion of large amounts of caspase-8 directly processing effector caspases. 
• type II cells, in which minor amounts of active caspase-8 induce apoptogenic acti-
vity of mitochondria, e.g. by cleavage of BID. 
Further problems might arise from other characteristics of the established model sys-
tems. Drug-resistance, for example, just describes the phenomenon and can be medi-
ated by overexpression of detoxifying proteins (MDR-type), overexpression of anti-
apoptotic proteins, functionally inactive pro-apoptotic proteins or other mutations or de-
letions in yet unknown proteins associated with the apoptotic machinery. In line with
this, it was also investigated whether CD95/Fas signalling is involved in taxol- and epi-
rubicin-induced apoptosis in BJAB cells. This was necessary because death pathways
in B-lymphoma cell lines, unlike in T-cells, have been less intensively characterized.
BJAB cells do not express significant amounts of CD95 ligand mRNA after challenge
with the cytotoxic drug epirubicin (Daniel, PT, unpublished data). This might indicate
the exclusion of CD95/Fas induced apoptosis via paracrine or autocrine Fas-signalling.
Additionally, epirubicin-induced cell death was not influenced by antagonistic anti-
CD95 antibodies (Daniel, PT, unpublished data). By this means, BJAB cells represent
a suitable model system to investigate CD95-independent drug-induced apoptosis and
further manipulation, e.g. generation of restistant clones, is not necessary. 
As described, cytostatic drug treatment of BJAB/mock cells induces several character-
istics of the mitochondrial apoptotic pathway. Nonetheless, as evidence for cross-talk
between the two main apoptotic pathways exists, it could not be excluded that the pri-
mary cause for apoptosis is FasR ligation. Activation of the CD95/Fas pathway leading
to cleavage of procaspase-8 after recruitment to the CD95/Fas DISC was investigated
by Western blot analysis of caspase-8. Surprisingly, caspase-8 processing was clearly
detected after challenging BJAB/mock cells with taxol or epirubicin. Since caspase-8 is
reported to be the predominant initiator caspase in CD95/Fas-mediated apoptosis fur-
ther investigation had to be made and experiments using BJAB cells stably transfected
with a dominant negative mutant of FADD, FADDdn, were performed. FADD is the92
Discussion VIIIadaptor molecule necessary for formation of the CD95/Fas DISC and associates with
the trimerized FasR (Walcac and Krammer, 2000) thereby recruiting caspase-8. Simi-
lar to caspase-9 in the mitochondrial DISC caspase-8 autoproteolyses and active
caspase-8 heads for effector caspases to start the apoptotic machinery.
The results obtained in FADDdn-transfected cells were similar to those derived from
BJAB cells. DNA fragmentation, caspase-8 and caspase-3 processing and loss of mi-
tochondrial membrane potential was readily detected using the suitable assays. This
shows that FasL signalling, either autocrine or paracrine, is not involved in drug-in-
duced apoptosis in BJAB cells. No significant differences in the drug-induced apoptosis
pathway in mock transfectants compared with FADDdn transfected cells could be de-
tected and CD95/Fas signalling therefore can not be necessary for induction of apop-
tosis by cytostatic drugs in this experimental setup. 
VIII-1.3 CASPASE-8 AS DOWNSTREAM TARGET
Caspase-8 activation after drug treatment of BJAB cells apart from CD95/Fas signal-
ling was shown for the first time. However, the presented data clearly confirmed results
showing that Fas-resistent Jurkat T cells are still succeptible to drug-induced apoptosis
(Wesselborg et al., 1999). Nevertheless, further experiments were carried out to eluci-
date the circumstances of caspase-8 processing in drug-induced apoptosis. It is rea-
sonable to assume that caspase-8 is processed as downstream target in the
mitochondrial apoptotic pathway, probably leading to an amplification loop in the
caspase cascade. To address this question, BJAB cells were treated with the respec-
tive cytostatic drugs in the presence or absence of the specific caspase inhibitors Z-
DEVD-fmk and Z-WEHD-fmk. As a positive control PARP cleavage was shown to be
substantially inhibited by Z-DEVD-fmk whereas Z-WEHD-fmk showed no effect on
PARP cleavage indicating that Z-DEVD-fmk clearly blocks caspase-3-like cleavage ac-
tivity. In line with the hypothesis of caspase-8 processing as a downstream event, Z-
DEVD-fmk also blocked formation of the 18 kDa mature subunit of caspase-8 after
drug-induced apoptosis in BJAB/mock cells. This clearly indicates that caspase-3-like
activity is necessary for caspase-8 processing in drug-induced apoptosis of BJAB cells.
Furthermore, it can be reasoned that caspase-8 and caspase-3 are cytoplasmatic pro-
teins and this cleavage is in line with experiments performed by Slee et al (Slee et al.,
1999). Within their publication, Slee et al. report caspase-8 processing downstream of
caspase-3, at least in T cell extracts in vitro.
But, as caspase inhibitors are specific rather than selective, this positioning of caspase-
8 downstream of caspase-3 in drug-induced apoptosis of BJAB/mock cells had to be
confirmed. This was done using a cell free extract assay system. In this system, the
mitochondrial apoptotic cascade can be induced by addition of cytochrome c and dATP
leading to formation of the mitochondrial DISC and subsequent caspase-9 and93
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that caspase-8 processing and activation followed a significant slower kinetic than
caspase-3 activation. This shows that a) procaspase-8 is processed after mitochondri-
al induction of the caspase cascade in the cell free system, b) this processing is accom-
panied by caspase-8-like cleavage activity and c) because of the slower kinetics
caspase-8 activity might follow caspase-3 activation. In another experiment pro-
caspase-3 was immunochemically depleted from the cell free extract prior to activation
of the caspase cascade. As assumed caspase-3-like cleavage activity in the depleted
extracts was significantly reduced showing that caspase-3 removal was succesfull.
Moreover, caspase-8 processing was diminished. This shows that processing of pro-
caspase-8 in cell free extracts relies on active caspase-3, confirming the observation
in drug-treated BJAB/mock and BJAB/FADDdn cells. 
VIII-1.4 PROCASPASE-8 PROCESSING IN NALM6 AND REH CELLS
As all the experiments were performed in only one cell line the question arose whether
procaspase-8 processing after drug-induced apoptosis is a general phenomenon or is
just restricted to BJAB cells. In order to answer this question, two B-lymphoma cell
lines, namely NALM6 and REH, were used to examine the effects of drug treatment in
these cells. It was shown that, after challenged with taxol or epirubicin, both cell lines
show significant DNA fragmentation confirming induction of the apoptotic machinery.
Loss of mitochondrial membrane potential after drug treatment was also assayed and
clearly detected as soon as 24 hs after application of the respective cytostatic drugs.
Procaspase-8 processing in NALM6 and REH cells after treatment with 0.12 µM taxol
and 1.85 µM epirubicin after 24 hs and 48 hs was investigated by Western blot analy-
sis. The mature p18 subunit of caspase-8 was detected in REH cells after 24 hs expo-
sure to epirubicin and after 48 hs exposure to taxol. NALM6 cells were less susceptible
to drug-induced caspase-8 processing and the 18 kDa subunit was only detected after
48 hs of epriubicin treatment. This reflects the results obtained in a caspase-8 activity
assay using the caspase-8-specific colorimetric substrate Ac-IETD-pNA. Caspase-8
activity was clearly detected in REH cells treated with epirubicin for 24 hs and with taxol
for 48 hs. NALM6 did not show enhanced caspase-8 activity as compared with controls
at these points of time. This confirms the correlation of caspase-8 processing detected
in Western blot analysis with Ac-IETD-pNA cleavage activity. However, processing of
procaspase-8 after drug-induced apoptosis in NALM6 and REH was hereby confirmed
as both cell lines showed appearance of the 18 kDa subunit of caspase-8 after epiru-
bicin-induced apoptosis, although taxol-induced procaspase-8 processing was less ef-
ficient.94
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Although active caspase-3 can not be rendered directly responsible for caspase-8 pro-
cessing in the in vitro mitochondrial apoptotic cascade it is obviously necessary for
downstream processing of procaspase-8. Nevertheless, additional experiments should
elucidate the apoptotic cascade in BJAB cells in more detail. For example, it should be
investigated whether caspase-3 itself or caspase-6 or caspase-7 mediate procaspase-
8 processing. Using specific inhibitors it should be possible to investigate the substrate
specificity of the acting caspase, Z-VEHD-fmk for caspase-6 and Z-DEVD-fmk for
caspase-3 and -7. Unfortunately, caspase-3 and -7 display the same preferred cleav-
age sequence and this experiment would only allow differentiation between caspase-6
and caspase-3 or caspase-7. Even determination of the exact cleavage site in
caspase-8 would not be sufficient. It can be speculated that caspase-7 is unlikely to
cleave caspase-8 because caspase-7 in cells undergoing apoptosis is located in the
microsomal fraction (Zhivotovsky, 1999). Furthermore, immunoprecipitation of
caspase-3 prior to activation of the mitochondrial apoptotic cascade in vitro blocked
caspase-8 processing whereas caspase-7 is activated in parallel with caspase-3 in vi-
tro. On the basis of the performed experiments it can be concluded that processing of
caspase-8 after drug-induced apoptosis is most likely mediated by caspase-6 as
shown in vitro by Slee et. al. (1999).
It would be interesting to further investigate upstream events in drug-induced apopto-
sis, e.g.  BID cleavage or even signalling proteins located upstream of mitochondrial
depolarization, as well as downstream events, e.g. other caspases, not involved in mi-
tochondrial induced apoptosis, or caspase substrates. Additionally, a caspase-8 defi-
cient cell line or functionally inactive mutant of caspase-8 could provide evidence for
implications of caspase-8 activation after drug-induced apoptosis, although this could
also be adressed by the use of Z-IETD-fmk as a specific caspase-8 inhibitor. 
VIII-2 D4-GDI IN DRUG-INDUCED APOPTOSIS
VIII-2.1 DISCUSSION OF PRESENTED RESULTS
Within this study D4-GDI was identified to be specifically proteolyzed by caspase-3 af-
ter drug treatment of BJAB/mock cells with taxol or epirubicin. This was achieved in the
following order: First, significant decrease in intensity of the spot representing D4-GDI
in BJAB/mock cells incubated in the presence of taxol or epirubicin was detected after
high resolution 2DE PAGE. The identitiy of this spot was examined using mass spec-
trometric analysis and data bank search and identified as D4-GDI. Then, conventional
Western blot analysis of samples from a time course experiment revealed the appear-
ance of a distinct band with a lower apparent molecular weight upon drug treatment of
BJAB/mock cells. In order to elucidate the identity of this band, Western blot analysis95
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three spots. According to the specificity of the used Ab one of these spots was as-
sumed to represent D4-GDI, as already identified by mass spectrometry, another im-
munoreactive spot was assigned to rho-GDI 1 and the third spot should represent a
fragment of either rho-GDI 1 or, more likely, of D4-GDI, as D4-GDI was already detect-
ed to display decreased concentration upon drug treatment. Computer aided image
processing allowed correlation of results from Western blot analysis and 2DE PAGE
and lead to the identification of the spot representing rho-GDI 1. Furthermore, the ob-
served fragment was definitively assigned to D4-GDI as shown by mass spectrometric
analysis. This showed clearly, that D4-GDI is specifically proteolyzed during drug-in-
duced apoptosis of BJAB/mock cells. Additionally, as no significant decrease in the in-
tensity of the spot representing rho-GDI 1 was detected, degradation of rho-GDI 1
during apoptosis was excluded. Despite high homology to D4-GDI, rho-GDI 1 seems
to be cleavage resistant thereby confirming that the apoptotic machinery selectively tar-
gets different proteins in the cell. Nonetheless, caspase-3 (Na et al., 1996) and
caspase-1 (Danley et al., 1996) had been reported to mediate D4-GDI cleavage during
apoptosis. Thus, it was further investigated whether caspase-1 or caspase-3 was re-
sponsible for appearance of the D4-GDI fragment. Western blot analysis was per-
formed to examine activation of caspase-1 upon challenge of BJAB/mock cells with
taxol or epirubicin. Although decrease of procaspase-1 in this samples was detected
no significant increase of the band detected with the Ab specific for the mature subunit
of caspase-1, p20, was seen. Additionally, caspase-1 like cleavage activity was neither
detected in drug-treated BJAB/mock cells nor in cell free extracts activated by addition
of cytochrome c, indicating that caspase-1 is not activated in the mitochondrial apop-
totic cascade. This is in accordance with the in vitro ordering of the caspase cascade
by Slee et al.(Slee et al., 1999) In vitro activation of extracts clearly showed specific
cleavage of D4-GDI thereby providing evidence for caspase-3-mediated cleavage of
D4-GDI. Taken together, these results strongly indicated caspase-3-mediated cleav-
age of D4-GDI in BJAB/mock cells challenged with taxol or epirubicin and in cell free
extracts activated by addition of cytochrome c and dATP. This assumption was further
confirmed using the caspase-3 and caspase-1 specific peptide inhibitors Z-DEVD-fmk
and Z-WEHD-fmk. In these experiment exposure of BJAB/mock cells to the caspase-
3 specific inhibitor during drug-treatment resulted in significant decrease in intensity of
the D4-GDI-fragment band in contrast to exposure to the caspase-1-specific inhibitor
Z-WEHD-fmk. Furthermore, immunochemical depletion of cell free extracts using a
caspase-3 specific Ab and application of the caspase-3-specific colorimetric substrate
as competitive inhibitor in in vitro experiments diminished D4-GDI cleavage. These re-
sults clearly indicate caspase-3-mediated cleavage of D4-GDI in BJAB/mock cells after
exposure to cytostatic drugs and upon in vitro activation of the mitochondrial apoptotic96
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vealed the presence of the peptide containing the published caspase-1 cleavage site
thereby undoubtedly demonstrating caspase-3 as the acting protease. In detail,
caspase-1 cleaves D4-GDI at aa-position 59 whereas caspase-3 acts on aa-position
19 and the D4-GDI fragment represents the C-terminal part of the protein. Thus, the
presence of the peptide containing the caspase-1 cleavage site excludes caspase-1
mediated proteolysis of D4-GDI.
VIII-2.2 IMPLICATIONS OF D4-GDI CLEAVAGE IN DRUG-INDUCED APOPTOSIS
Cleavage of the GDP dissociation inhibitor D4-GDI has been demonstrated in CD95/
Fas-induced (Na et al., 1996), anti-IgM mediated (Rickers et al., 1998), etoposide- and
staurosporine-induced (Krieser and Eastman, 1999) apoptosis and the relevance of
this cleavage for cytoskeletal changes has been discussed. Three GDP dissociation in-
hibitors are known so far: rho-GDI 1, rho-GDI 2 (D4-GDI), and rho-GDI 3. Rho-GDI 3
is not expressed in haematopoietic tissues in contrast to rho-GDI 1 and  D4-GDI. Rho-
GDI and D4-GDI both are reported to associate with cdc42Hs, rhoA, rac1 and rac2 in
vitro but in contrast, after microanalytic liquid chromatography of human myelomono-
cytic cytosol none of this proteins was found in the 45 kDa - 50 kDa complex containing
D4-GDI (Gorvel et al., 1998). This indicates that D4-GDI primarily acts on a yet uniden-
tified protein. Interestingly, the existence of two GTPases belonging to the rho sub-
group, TTF (Dallery et al., 1995) and rhoE (Foster et al., 1996), has been described. At
least TTF interaction with D4-GDI is reasonable because TTF is expressed in a restrict-
ed manner in hematopoietic cells (Dallery et al., 1995) and D4-GDI can solubilize over-
expressed TTF from membranes (Gorvel et al., 1998). But detailed knowledge about
D4-GDI regulating activities remains elusive.
However, rho-GTPases are involved in the regulation of integrin activity and in the or-
ganization of the actin cytoskeleton (Hall, 1994, Narumiya, 1996) and three types of
regulator proteins are known to act on the different rho-GTPases: GTPase-activating
Proteins (gaps), guanine-nucleotide exchange factors (gefs) and GDP-dissociation in-
hibitors (GDIs). Additionally, at least for the rab-cycle, a protein has been discovered
that mediates dissociation of the GDI from the GTP-binding protein, called GDF (GDI
dissociation factor). Although the complex signalling pathways and molecular interac-
tions within the family of small GTP-binding proteins has not yet been completely elu-
cidated, the small GTP binding proteins have in common, that they act as molecular
switches. The GTP-bound state is the ’active’ state and they are ’inactive’ in the GDP-
bound state. This is especially true for ras which is involved in cell-cycle regulation.
What impact D4-GDI cleavage has on regulation of the cytoskeleton is not clear. It has
been shown that the N-terminal domain of rho-GDI 1 blocks exchange of guanosine-
nucleotide whereas interaction with rho-proteins is restricted to the C-terminal part. De-97
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change and release of cdc42 from membrane bilayers whereas deletion of the first 25
aa showed no effect. Correlated with D4-GDI, cleavage by caspase-1 corresponds to
deletion of  the larger aminoterminal part leading to defective GDP-exchange regula-
tion and cleavage by caspase-3 can be compared to deletion of the first 25 aa in rho-
GDI 1. Interestingly, the D4-GDI fragment resulting from caspase-3 mediated cleavage
is reported to translocate to the nucleus but overexpression of an uncleavable mutant
did not show any influence on cell death as determined by staining with Hoechst 33342
(Krieser and Eastman, 1999). Therefore, further studies to investigate the role of D4-
GDI and its cleavage during apoptosis should be performed, because it is unlikely that
specific cleavage and translocation of the D4-GDI fragment to the nucleus is just an
epiphenomenon. Especially the influence of GDI-cleavage on the organisiation of the
cytoskeleton should be investigated on basis of the facts given above. 
VIII-2.3 THE CYTOKINE REPONSE MODIFIER A (CRMA)
Experiments were also performed with BJAB cells stably transfected with the cytokine
response modifier A. CrmA belongs to the serpin family of protease inhibitors (Pickup
et al., 1986) and has been shown to block mature caspase-8 and caspase-1 activity
(Tewari et al., 1995). Therefore, it was first surprising to detect strong effects of crmA
on cytostatic drug-induced apoptosis in BJAB/crmA cells as compared to vector control
transfected cells although caspase-1 activation was excluded (see above) and
caspase-8 activation has also been shown to be a downstream event in this experi-
mental setup. However, speculations can be made regarding this outcome. On the one
hand these results rise the possibility that crmA also significantly influences activity of
caspases involved in the mitochondrial apoptotic pathway, although the inhibitory con-
stant for inhibition of caspase-9 activity is about two orders of magnitude higher than
that for inhibition of caspase-8 (Ekert, 1999). On the other hand, it might be concluded
that caspase-8 activation, although representing a downstream event in drug-induced
apoptosis of BJAB cells, is important for progression of the apoptotic program for ex-
ample by leading to additional caspase-3 activation in an amplification loop. Neverthe-
less, with respect to the presented results it can not be concluded conceivably whether
crmA blocks the mitochondrial apoptotic pathway by inhibition of mature caspase-9 or
caspase-3 itself or by abrogation of an amplification loop due to downstream process-
ing of caspase-8. This question could be answered by the use of caspase-8 specific
inhibitors or BJAB cells overexpressing an inactive mutant of caspase-8. Additionally,
in vitro experiments could be performed using cell extracts immunochemically depleted
of procaspase-8 prior to activation. This would further elucidate the influence of
caspase-8 processing on downstream events in the mitochondrial apoptotic cascade. 98
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Using high resolution 2DE PAGE some apoptosis associated proteins have been iden-
tified using subtractive analysis within this study. Procaspase-3 concentration is shown
to decrease after drug-induced apoptosis of BJAB/mock cells which is consistent with
data presented in the literature and this study. Moreover, specific cleavage of D4-GDI,
as shown by decreased intensity of the spot representing D4-GDI and increased inten-
sity of the resulting fragment, was detected in high resolution 2DE PAGE gels (as al-
ready discussed above). The remaining proteins, which have been detected by
subtractive analysis of gels derived from drug-treated and untreated BJAB/mock cells
are discussed in detail below. These are β-Actin, which has also been reported as a
caspase-3 substrate during apoptosis, cyclophilin A (cypA), t-complex binding protein
subunit δ (TCPD), desoxyuridine 5’-triphosphate nucleotide hydrolase (DUT), nucleolin
and RNA polymerase B transcription factor 3 (BTF3).
VIII-3.1 PROCASPASE-3 (ICE3)
Although processing and activation of caspase-3 as the major effector caspase is well
documented the identification of the spot #32 representing procaspase-3 in high resol-
tution 2DE PAGE gels is a great advantage for future investigations. Most of the marker
proteins associated with apoptosis identified on high resolution 2DE gels so far repre-
sent caspase substrates and are therefore presumably located downstream of effector
caspases in the apoptotic cascade. Caspase-3 activation is at least one step upstream
of degradation of several of the already identified caspase substrates and decreased
spot intensity of the spot representing procaspase-3 in 2DE PAGE gels now can be in-
terpreted as induction of apoptosis in these cells. Moreover, it now might be possible
to discriminate between apoptosis related variation of spot intensity in general and
changes accompanied by decrease of procaspase-3 concentration. This gives further
information about the mechanisms responsible for changes in spot intensity detected
by subtractive analysis. 
However, a procaspase-3 concentration above the detection limit of analytical silver-
staining is a precondition for this implications. 
VIII-3.2 β-ACTIN (ACTB)
The cytoskeleton consists of microtubules (α- and β-tubulin), actin filaments (β- and γ-
actin) and intermediate filaments. Actin filaments are located within the plasmamem-
brane and mediate changes of plasma membrane shape together with actin-binding
proteins such as myosin (Michal, 1999). 
In 2DE PAGE gels two spots were identified as actin fragments, either N-terminal or C-
terminal. The appearance of the C-terminal fragment (spot #6) was readily detected in
lysates derived from cytostatic drug-treated BJAB/mock cells after 2DE PAGE and af-99
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that formation of the C-terminal actin fragment is located downstream of caspase acti-
vation and caspases therefore represent the enzyme family responsible for actin pro-
teolysis. Proteolysis of β-actin after drug-induced apoptosis in BJAB/mock cells is in
accordance with data presented in the literature. Apoptosis is accompanied by dramat-
ic reorganization of the cytoskeleton, which is followed by morphological changes and
cellular fragmentation (Brancolini et al., 1995). It has been suggested that the microfil-
ament is involved in morphological changes in apoptosis by some inhibitor studies
(Cotter et al., 1992). Several cytoskeletal proteins (such as Gas2, gelsolin, β-catenin,
fodrin, actin, PAK-2) are reported to be proteolytically cleaved by caspases during ap-
optosis (Brancolini et al., 1995, Brancolini et al., 1997, Cryns et al., 1996, Kayalar et
al., 1996, Kothakota et al., 1997, Martin et al., 1995, Mashima et al., 1995, Rudel and
Bokoch, 1997). However, in some systems, the morphological changes were shown to
be independent of the apoptotic proteases (McCarthy et al., 1997, Mills et al., 1998,
Toyoshima et al., 1997). Mashima et al. showed that cytoskeletal actin is the substrate
of caspases (Mashima et al., 1995; Mashima et al., 1995). Furthermore, they report on
the induction of morphological changes by expression of the 15 kDa C-terminal frag-
ment of β-actin (Mashima et al., 1999). 
The detection of a N-terminal fragment at slightly higher apparent molecular weight
(spot #11) is restricted to samples derived from in vitro activation of cell extracts. This
is in clear contrast to in vivo proteolysis of β-actin where it is shown that cleavage only
results in the detected 15 kDa C-terminal fragment and a 31 kDa N-terminal fragment
(Mashima et al., 1999). These data might reflect that in vitro activated extracts are an
artificial system which does not reflect exactly the in vivo situation during apoptosis. Ad-
ditional cleavage of the 31 kDa fragment during in vitro activation might arise from
membrane disruption during extract preparation. However, another conclusion is, that
in vitro cleavage of proteins by distinct caspases at distinct cleavage sites might not al-
ways occur in vivo. Thus, experiments carried out with purified recombinant proteins,
which are even more artificial than experiments using cellular extracts, should always
be confirmed under in vivo conditions.100
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Cyclophilin was first identified as the intracellular receptor for the immunosuppressant
drug cyclosporin A (Handschumacher et al., 1984). Cyclophilins comprise a highly con-
served, ubiquitous family of proteins and range in size from 15 kDa to 40 kDa (Kieffer
et al., 1992, Hornbogen and Zocher, 1995). These proteins are localized to the cyto-
plasm (Handschumacher et al., 1984), mitochondria (Rassow et al., 1995) the nucleus
(Ryffel et al., 1991, McDonald et al., 1992) and endoplasmic reticulum (Price et al.,
1991). Various activities have been reported for cyclophilins, including action as chap-
erones (Freskgard et al., 1992, Baker et al., 1994), as chemotactic agents (Xu et al.,
1992) and as stress response proteins (Sykes et al., 1993, Marivet et al., 1994). More-
over, cyclophilin A is reported to bind to the p55 gag protein of human immunodeficien-
cy virus (Luban et al., 1993) and appears to be necessary for successful infection (Thali
et al., 1994, Franke et al., 1994). Additionally Montague et al (Montague et al., 1994)
supposed a nuclease activity associated with the cyclophilin proteins based on se-
quence and structural similarities between nuc18 and the cyclophilin family. This as-
sumption was later experimentally confirmed (Montague et al., 1997).
In this context, it is interesting that after drug-induced apoptosis an additional spot rep-
resenting cyclophilin (spot #13) had been detected on 2DE PAGE gels. This spot is lo-
cated at the same apparent molecular weight as compared with the two high abundant
spots also representing cyclophilin A (Otto et al., 1998).
This is in agreement with a supposed alteration of the post-translational modification in
cyclophilin A during apoptosis which is probably necessary for activation of the DNase
activity (Montague et al., 1997). However, the exact kind of post-translational modifica-
tion has not been unraveled yet. Mass spectrometric analysis of spot #13 might thus
reveal the presence of a post translational modification in cyclophilin A upon drug treat-
ment. Another possibility is loss of a distinct modification which might be present in the
two other spots representing cyclophilin A. However, this supposed modification is far
more reasonable than proteolysis by caspases while spot #13 was not detected in 2DE
PAGE gels derived from in vitro activated extracts of BJAB/mock cells (see Fig. 39). 
13
cypA
cyp
A
Fig. 52: Cyclophilin A in 2DE PAGE gels of apoptotic cells. The position of cyclophilin A on 2DE
PAGE gels is indicated as well as the position of spot #13 specifically appearing after drug-induced ap-
optosis of BJAB/mock cells (compare Fig. 39). cypA = cyclophilin A.101
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Spot #28 was identified as tcpd (t-complex binding protein, subunit δ) located at an ap-
parent molecular weight of ~25 kDa. This is in strong contrast to the theoretical molec-
ular weight calculated from the aa-sequence, which is 57.8 kDa (swissprot: p50991). It
is therefore assumed that spot #28 represents a fragment of the δ-subunit of the t-com-
plex binding protein. Intensity of the spot representing this fragment specifically in-
creases after drug-induced apoptosis in BJAB/mock cells as compared with the
intensity of surrounding spots. An increased intensity of this spot is also observed upon
caspase activation in cell free extracts after addition of cytochrome c and dATP (see
Fig. 38). This indicates that formation of the tcpd-fragment is an apoptosis-related
event and results from caspase activation. Mass spectrometric analysis of the spot ex-
clusively detected N-terminal peptides (representing aa-residues 66-79, 80-89, 161-
174 and 194-206). This suggeests that the assumed proteolytic cleavage occurs up-
stream of aa-position 206 because identified peptides.
Tcpd belongs to the tcp-1 family of proteins which act as molecular chaperones for tu-
bulin, actin and probably some other proteins (Rommelaere et al., 1993). These pro-
teins are significantly related to the groEL chaperonin family, which is known to assist
in protein folding in an ATP-consuming manner. However, not much is known about
these proteins and therefore it can only be stated that appearance of the tcpd-fragment
on the basis of the given data is coupled to drug-induced apoptosis in BJAB/mock cells
as well as induction of the mitochondrial caspase cascade in cell free extracts of these
cells. With regard to the endorsed function of tcp-1 family proteins its proteolytic deg-
radation during apoptosis might play a role for a) the reorganization of the cytoskeleton
(Brancolini et al., 1995) and b) the degradation of ATP-consuming proteins (e.g.
PARP).
VIII-3.5 DESOXY URIDINE 5’-TRIPHOSPHATE NUCLEOTIDE HYDROLASE (DUT) 
The nuclear isoform of dut (desoxyuridin 5’ triphosphate nucleotide hydrolase) is rep-
resented by spot #17. This spot displayed decreased intensity after drug treatment of
BJAB/mock cells but no significant changes were detected in in vitro acitvated cell free
extracts in comparison with non-activated extracts (Fig. 36). On this basis, it is appro-
priate to assume that decrease occurs due to degradation rather than proteolysis by
caspases. Nevertheless, in the context of apoptosing cells, degradation of DUT does
make sense. 
dUTPase removes dUTP from the DNA biosynthetic pathway by catalysing its hydrol-
ysis to dUMP and PPi. Simultaneously, this reaction provides dUMP for de novo syn-
thesis of thymidylate (Lindahl, 1982). dUTPase is important for prokaryotic, eukaryotic
and viral systems while it is essential for the viability of E.coli and S.cerevisiae and ef-
ficient DNA replication in viral systems (el-Hajj et al., 1988; Gadsden et al., 1993; Pyles102
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thymidylate synthesis by thymidylate synthase (TS) and blocking of this enzyme results
in accumulation of excess dUTP (Beck et al., 1986; Curtin et al., 1991; Ingraham et al.,
1986; Sedwick et al., 1981). This leads to misincorporation of dUMP into DNA during
DNA replication and repair, resulting in DNA fragmentation and subsequent cell death
(Curtin et al., 1991).
Taken together degradation of DUT once more reflects the general character of apop-
tosis, but in a slightly different manner. Since DUT appears to be degraded rather than
specifically proteolyzed it can be argued that DUT protein concentration is no longer
maintained in apoptosing cells. DUT mRNA levels and protein content are tightly reg-
ulated and coincide with nuclear DNA replication status (Ladner and Caradonna,
1997). Degradation of DUT should therefore be a fast and continuous process. This
process of degradation presumably is maintained during apoptosis whereas biosynthe-
sis of DUT protein is no longer initiated. These two conditions in combination may lead
to the observed decrease in DUT content in cells undergoing apoptosis.
VIII-3.6 NUCLEOLIN (NUCL)
Spot #12 was identified as nucleolin by sequencing two peptides located in the C-ter-
minal part of the full length protein. As the calculated molecular weight for nucleolin is
~77 kDa and the examined spot is located in the low molecular weight part of the 2DE
PAGE gels the identified spot clearly represents a fragment of this multifunctional pro-
tein (apparent MW < 15 kDa). Comparison of protein patterns derived from separated
samples of drug-treated BJAB/mock cells and in vitro activated cell free extracts shows
that this fragment not only appears upon drug-induced apoptosis but additionally after
in vitro initiation of the mitochondrial caspase cascade. This is important with respect
to the fact, that nucleolin inherits an autoproteolytic activity (Srivastava and Pollard,
1999). Specific increase of the nucleolin-fragment content after in vitro activation indi-
cates that this event is mediated or initiated by caspase activation.
Nucleolin is a high abundant nuclear, non-histone phosphoprotein (Bugler et al., 1982;
Shaw and Jordan, 1995) and active nucleolin comprises about 5 % of nuclear protein
in dividing eukaryotic cells (Srivastava and Pollard, 1999). It exerts numerous distinct
biochemical activities including organization of nuclear chromatin (Erard et al., 1990),
packaging of preRNA, transcription of rDNA (Borer et al., 1989; Bouche et al., 1987;
Caizergues-Ferrer et al., 1989; Herrera and Olson, 1986; Jordon, 1987) and ribosome
assembly (Jordon, 1987). In addition, nucleolin exhibits autodegradation (Chen et al.,
1991; Fang and Yeh, 1993; Lapeyre et al., 1987; Olson et al., 1990), DNA and RNA
helicase activities (Tuteja et al., 1995) and DNA-dependent ATPase activity (Tuteja et
al., 1997). Nucleolin belongs to a large family of RNA binding proteins including heter-
ogenous nuclear ribonucleoproteins (hnRNPs), mRNA polyadenylate binding protein103
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ASF and SF2 (Ge et al., 1991; Krainer et al., 1991).  For hnRNP C1/C2 which is related
to nucleolin and which also is involved in pre-mRNA processing,  specific cleavage has
been reported (Wang et al., 1996; Waterhouse et al., 1996). Nucleolin is physiologically
cleaved by granzyme A. Truncated nucleolin then activates autolytic endonucleases fi-
nally leading to DNA fragmentation (Arends et al., 1990, Smith et al., 1994). The spe-
cific cleavage of nucleolin after drug-induced apoptosis is further underlined by the
identification of nucleolin to be associated with anti-IgM induced apoptosis in another
human Burkitt-lymphoma cell line (Brockstedt et al., 1998). In proliferating cells nucle-
olin content is regulated by the expression of a proteolysis inhibiting protein that pre-
vents self-degradation (Chen et al., 1991). It therefore might be possible that the
caspases do not directly act on nucleolin but proteolyse this inhibitor.
VIII-3.7 RNA POLYMERASE B TRANSCRIPTION FACTOR 3 (BTF3)
One of the spots most sensitive to induction of apoptosis was identified to represent the
RNA polymerase transcription factor 3 (BTF 3, spot #16, Fig. 39). This protein migrates
on 2DE gels at ~17 kDa. In response to drug treatment of BJAB/mock cells this protein
spot nearly disappears. The same is true for BTF3 concentration in 2DE PAGE gels
derived from in vitro activated extracts of BJAB/mock cells. In conclusion, this response
is presumably due to proteolytic cleavage of BTF3 by caspases. This is in accordance
with published data (Brockstedt et al., 1999) in which it was shown that BTF3 is specif-
ically degraded after anti-IgM induced apoptosis in a subclone of the human B-cell lym-
phoma cell line BL-60. Data presented in this study additionally assigns this
degradation to accompany mitochondrial activation of the caspase cascade rendering
one of the caspases activated after in vitro activation responsible for BTF3 degradation,
either  caspase-9 or one of the effector caspases. Studies on a) which caspase medi-
ates degradation of BTF3, b) what the resulting fragments are and c) what conse-
quences rapid degradation of BTF3 bears for apoptotic cells would be promising aims
for further investigations. 104
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2DE PAGE is a widely used method for the separation of complex protein mixtures. Es-
pecially due to the commercial availability of 2DE PAGE systems and precast gels, it
has become a famous technique in diversive fields of life scienes. Because of its ability
to resolve more than 10000 polypeptides (Klose, 1995) in one integrated method, 2DE
PAGE has also become the heart of proteome analysis. Although 2DE PAGE probably
represents the most powerful technique for protein separation it also bears some se-
vere obstacles. These obstacles need to be overcome in the future to make it a com-
monly used procedure leading to results which are comparable among different
laboratories. Some of these problems also arose during the investigations presented
above and are discussed in detail below. These include sample preparation, gel prep-
aration, reproducibility and sensitivity. In this study exclusively the system purchased
by WITA GmbH was used and therefore references to other 2DE PAGE systems are
merely of theoretical nature.
Although some problems arose concerning the reproducibility of 2DE PAGE gels this
method displays numerous advantages which make it an outstanding technique. Be-
sides the high resolution power it can be combined with Western blot analysis. This al-
lows application of 2DE PAGE to answer questions of general concern as well as
specific questions, as done in this work by immunochemical detection. In a specific kind
of proteomic approach it was investigated whether proteins are expressed/degraded
specifically after drug-induced apoptosis. Some of these proteins, which mostly are as-
sumed to be caspase substrates, have been identified. In a more specific case, the
identity of an immunoreactive band was unraveled using 2DE PAGE. Although exten-
sive computer aided image processing had to be performed to correlate results ob-
tained by Western blot analysis with those obtained by silverstaining of 2DE PAGE gels
applicability of this approach was clearly demonstrated. As a further result it can be
suggested that in the first and second dimension PAGE problems arise from the lability
of the polyacrylamide matrix. Swelling and shrinking of the second dimension during
the blotting or staining procedure should be minimized probably by using an inert, flex-
ible and to some extent permeable support, e.g. a nylon mesh or membrane. This
would probably abolish changes in gel-size during these procedures and increase re-
producibility and gel matching. 
Some kind of flexible support would also be helpful in handling the first dimension. IEF-
gels consist of 4 % acrylamide and handling must be performed with much care. In
most cases, changes in gel length can not be prevented. Since this stretching during
transfer to the second dimension SDS-PAGE gel is not proportional over the whole gel
length it results in varying spot patterns. This, in turn, probably represents one of the
problems leading to inefficient automatic gel processing.105
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mated gel stainer apparatus. The gel staining procedure according to Heuckeshofen
(Heuckeshofen and Dernick, 1985) takes about 3 hs. This is a time-consuming tech-
nique and automated staining would not only diminish laborous gel handling but also
enhance reproducibility. 
Mass spectrometry is one of the most sensitive methods for protein identification and
characterisation. However, sample preparation hampers efficient application of this
method. Although sensitive staining methods allow detection of spots with very low pro-
tein content and this amount of protein would theoretically be enough for mass spec-
trometric identification this aim often is not achieved. This can be attributed to
difficulties in handling samples with low protein content, e.g. adherence of protein to
the tubes. Therefore, even lowering the detection limit by application of. radioactive la-
beling might not be a successful approach to investigate unknown proteins. Even if cor-
relation of autoradiographic images and analytical silverstaining would be achieved a
large number of 2DE PAGE gels would have to be performed in order to pool sufficient
material for identification. To solve this problem, fractionation of samples prior to 2DE
PAGE seems to be the most promising attempt. A suitable fractionation procedure
should separate proteins on the basis of characteristics different from pI and molecular
weight. Subcellular fractionation would be an encouraging methodology, as well as
fractionation on the basis of hydrophobic interactions. Unfortunately, reproducibility of
sample preparation would be reduced by this additional steps. Cell sorting still seems
to represent another method for fractionation. Although it was stated that enrichment
of apoptotic cells did not lead to the desired enhancement of apoptosis-specific differ-
ences in 2DE PAGE gels, other characteristics than PS-exposure could be taken ad-
vantage of, e.g. loss of mitochondrial membrane potential. Another useful method to
obtain specific samples is, of course, immunochemical precipitation of protein com-
plexes.
VIII-4.1 CYTOSTATIC DRUG TREATMENT
However, increased sensitivity might only be necessary with regard to distinct ques-
tions. For example increased sensitivity would be of great value to examine drug-in-
duced effects on concentration of regulatory proteins. This is reasonable since
standard methodologies didn’t reveal other than downstream apoptosis-related pro-
teins. 
Albeit this, regulatory effects probably could be detected by tuning the experimental
and not the analytical system. Cytostatic drug-induced biochemical events are mostly
coupled to the cell cycle. As compared with more physiological death-inducing stimuli,
e.g. anti-IgM or FasL, cytostatic drug treatment takes a long time to induce apoptotic
changes. This is one more difficulty in detecting regulatory proteins. The cells have to106
Discussion VIIIpass a certain phase of the cell cycle for the drugs to take effect. Then, presumably
repair mechanisms are activated and after those the apoptotic signal is given from the
nucleus to the mitochondria. Therefore, several steps of signalling are located between
drug-induced damage and onset of the apoptotic events, leading to diversification of
the cells’ states. Thus, it would be an advantageous endeavor to synchronize the cells
prior to cytostatic drug treatment. In this case, momentum concentrations of regulatory
proteins should be above those in unsynchronised cells because all cells are captivat-
ed in the same phase of the cell cycle. This increased concentration of regulatory pro-
teins would probably be sufficient for detection in 2DE PAGE gels. 107
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